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ABSTRACT 
WALEERAT SUKARAWAN: Roles of WNT5A in Modulating Enamel Epithelium 
Tumorigenic Behavior 
(Under the direction of Dr. J. Timothy Wright) 
 
 
Odontogenic tumors originate from the remains of migrating enamel epithelium 
after the completion of normal tooth genesis. These enamel epithelium remnants exhibit 
the ability to recapitulate the events that occur during tooth formation. Several lines of 
evidence suggest that aberrance in the signaling pathways similar to the ones that are 
used during tooth development might be the cause of odontogenic tumorigenesis and 
maintenance. In this study we demonstrated that WNT5A (wingless-type MMTV 
integration site family, member 5A) expression was intense in both the epithelial 
component of ameloblastomas, the most common epithelial odontogenic tumor, and in 
the cervical loop area during normal human tooth formation. In addition, we discovered 
that enamel epithelium (LS-8) cell-derived clones expressing high (S) levels of WNT5A 
exhibited characteristics of tumorigenic cells, including growth factor independence, loss 
of anchorage dependence, loss of contact inhibition, tumor formation in vivo and 
increased cell migration when compared to controls (LS-8, EV). In order to elucidate the 
signaling pathways underlying these findings, pharmacological inhibitors specific for 
different downstream effectors in the known WNT5A signaling cascade were used in the 
in vitro cell growth transformation assay. We determined that specific JNK (c-Jun N-
terminal kinase) (SP600125) and ROCK (Rho-associated, coiled-coil containing protein 
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kinase) (Y27632) inhibitors suppressed the tumorigenic growth properties of enamel 
epithelium overexpressing WNT5A. Furthermore, strong phosphorylated JNK expression 
was detected in ameloblastomas in a similar pattern to WNT5A expression. Finally, 
increased levels of phosphorylated JNK expression was observed in enamel epithelium 
clones that overexpressed WNT5A as well as cells treated with recombinant WNT5A. 
Our data indicate that the Rho/JNK pathway could be the downstream signal of WNT5A 
in modulating tumorigenic behaviors of enamel epithelium. 
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REVIEW OF LITERATURE 
 
Regulation of enamel epithelium development (1-4) 
Mammalian teeth develop from the oral ectoderm and the underlying neural crest 
derived mesenchyme that progress through a series of interactions during the early stages 
of embryogenesis. The connection between enamel epithelium and dental mesenchyme 
involves a variety of cell signaling required for mediating cellular processes during the 
progression of tooth development. Tooth development can be divided into four major 
stages: initiation and the formation of dental placode, tooth morphogenesis, 
differentiation of tooth forming cells, and secretion of dentin and enamel matrices. The 
universal signals during embryonic development such as, Wingless-type MMTV 
integration site family (WNT), Sonic Hedgehog (SHH), Fibroblast Growth Factors 
(FGFs), Tumor Necrosis Factors (TNFs), and Bone Morphogenetic Proteins (BMPs) are 
used repetitively at different, advanced stages of tooth synthesis (5).  
 
Initiation of tooth development (5, 6) 
The enamel epithelium plays important roles during the very early stages of tooth 
formation. It serves as an early signaling center to induce the odontogenic potential in the 
dental mesenchyme. The first stage of tooth development begins with formation of the 
dental placode, and thickening of the epithelial band along the oral ectoderm (1). This 
process is necessary for defining the tooth forming area as teeth further develop along 
this structure. A variety of signaling molecules involving multiple signaling pathways are 
active in this dental placode (2, 3). Pitx2 is known to be the earliest dental marker 
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detected in future dental epithelial band (7). Shh and lymphoid enhancer binding factor 1 
(Lef-1) are expressed early at the primary epithelial band at E11 in mouse embryonic 
development. Tissue recombination studies in mouse reveal that the first inductive signal 
comes from the enamel epithelium and after E12 in mouse embryo development, 
induction switches to the dental mesenchyme (8, 9). 
 
Tooth morphogenesis (2, 10) 
As tooth development proceeds, the early thickening enamel epithelium 
invaginates into the underlying neural crest derived mesenchyme and induces the 
mesenchymal condensation leading to the formation of the tooth bud (bud stage). At the 
late bud stage, groups of non-dividing cells at the tip of tooth bud form important 
structures called “the primary enamel knot” (11-13). Studies show that over 50 genes 
belonging to BMPs, FGFs, SHH and WNT signaling pathways are transcriptionally 
active in the primary enamel knot (http://bite-it.helsinki.fi). These reciprocal signals 
direct the morphogenesis of the tooth. The surrounding enamel epithelium undergoes 
massive proliferation and the flanking epithelium proliferates further into the condensed 
mesenchyme and forms the cervical loops (cap stage). The epithelial in growth is called 
the enamel organ that will eventually differentiate to become ameloblasts and produce the 
tooth enamel. Mesenchymal cells that are surrounded by the cervical loop form the dental 
papilla and become the odontoblast and dental pulp cells. 
The final shape of the tooth crown is determined by the signals from the 
secondary enamel knot (2), a structure that is formed at the bell stage after the primary 
enamel knot is removed by apoptosis (14). Disruption of signals such as BMPs, 
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ectodysplasin A or FGFs during the bell stage leads to malformed cuspal patterns (15-
18).  
 
 
 
Figure 1.1 The cap and bell stages of tooth development. The enamel organ is 
expanding and undergoing massive histodifferentiation in the beginning of the early cap 
stage (left). The tooth has acquired its final shape and the structure is clearly 
distinguished in late bell stage (right). 
 
 
Tooth-specialized cell differentiation and mineralization (10) 
During tooth morphogenesis, the mass of tooth-specialized cells begin to 
differentiate into morphologically and functionally distinct components of tooth. Dentin 
and enamel, the mineralized structures of teeth, are formed by odontoblast and ameloblast 
differentiating from the mesenchyme and epithelium, respectively. The differentiation 
process begins at the bell stage of tooth development and continues in the cervical 
direction until the initiation of root development. The differentiation of odontoblasts and 
Oral epithelium Outer enamel  
epithelium 
Inner enamel epithelium Inner enamel epithelium 
Outer enamel 
 epithelium 
Stellate reticulum Stellate 
 reticulum 
Dental papilla Dental papilla 
Dental lamina 
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ameloblasts is also regulated by the reciprocal epithelial-mesenchymal interactions 
similar to the morphogenetic regulation. 
 
Odontoblasts 
Preodontoblasts form a single layer of cylinder-shaped cells adjacent to the inner 
enamel epithelium. During differentiation, the preodontoblasts elongate and polarize to 
become odontoblasts that are tall columnar cells. A major function of odontoblasts is to 
secrete the dentin extracellular matrix that is rich in mainly type I collagen and contains 
non-collagenous proteins including proteoglycans, glycoproteins and dentin 
sialophosphoprotein (DSPP) (19). Odontoblast differentiation is tightly regulated by the 
inner dental epithelium (2, 20, 21). Studies show that TGFβ1 and -3 and BMP2, -4 and -6 
can induce polarization of preodontoblasts and stimulate dentin matrix secretion (22, 23). 
 
Ameloblasts 
Enamel epithelium at the center of the enamel organ differentiates into the stellate 
reticulum cells that synthesize and secrete glycosaminoglycans. The cells at the periphery 
of the enamel organ differentiate into the outer enamel epithelium while the cells adjacent 
to the mesenchymal components differentiate into the inner enamel epithelium. 
Preameloblasts are derived from precursor cells of the inner enamel epithelium. During 
differentiation into secretory ameloblasts, they become highly columnar and polarized 
with oval-shaped nuclei elongated along the apical basal axis (1). 
Ameloblasts go through a series of differentiation stages. During the secretory 
stage, functional ameloblasts produce and secrete an abundant of specific proteins into 
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the enamel matrix that will be largely replaced by the deposition of calcium and 
phosphate during the secretory and maturation stages of enamel formation (24). The 
principal components of the enamel matrix can be classified into two major categories; 
amelogenin, and nonamelogenin proteins. Amelogenin makes up approximately 90% of 
the enamel matrix and is one of the key factors in controlling crystal growth (25). 
Amelogenin is essential for the organization of the crystal pattern (26). Ameloblastin, 
enamelin, tuftelin, laminin 5 as well as proteolytic enzymes are also secreted by 
ameloblast (27). When the enamel matrix deposition is complete, the secretory 
ameloblasts shrink in size. Some secretory ameloblasts undergo apoptosis after 
maturation and the remaining cells, together with the outer enamel epithelium, form a 
protective layer on the enamel until the time of tooth eruption (28). 
Ameloblast differentiation is tightly regulated by reciprocal epithelial-
mesenchymal communications as well as by the presence of functional odontoblasts 
and/or predentin-dentin (29). It was recently shown that the main signal from 
odontoblasts inducing ameloblast differentiation was BMP4, and that activin release from 
the dental follicle antagonized the effect of BMP4 (30). SHH is also necessary for 
regulating cell proliferation within the dental epithelium and controlling 
cytodifferentiation of preameloblasts (31).  
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Odontogenic tumor (32, 33) 
Odontogenic tumors are pathologies of the oral and maxillofacial region. They 
comprise a complex group of lesions from benign to malignant neoplastic tissue with 
metastatic capability. The term “odontogenic” refers to the derivation from a tooth-
forming apparatus. Similar to normal odontogenesis, odontogenic tumors exhibit several 
characteristics of epithelium-mesenchyme interactions that occur during tooth formation. 
According to the latest World Health Organization classification in July 2005 (34), 
odontogenic tumors are classified according to their tissues of origin into epithelial, 
epithelial-ectomesenchymal, and ectomesenchymal neoplasms. Tumors of odontogenic 
epithelium contained only odontogenic epithelium. Epithelial-ectomesenchymal or mixed 
odontogenic tumors are composed of both odontogenic epithelium and ectomesenchyme. 
Lastly, odontogenic ectomesenchymal tumors are mostly composed of ectomesenchymal 
elements, but some odontogenic epithelium may be present without any role in 
pathogenesis.  
 
Enamel epithelium remnants: origin of epithelial odontogenic tumor 
 After the formation of the crown, the inner and outer enamel epitheliums join 
together at the junctional zone called the cervical loop. Enamel epithelium continuously 
proliferates in an apical direction to the root area of the tooth and it is necessary for 
initiating the signals required for root formation. The fused extensions of these enamel 
epitheliums are call Hertwig´s epithelial root sheath.  After tooth formation is completed, 
this Hertwig´s sheath later becomes fragmented but leaves quiescent small islands of 
epithelial cells called epithelial rests of Malassez in the periodontal ligament space. 
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Epithelial rests of Malassez are the only odontogenic epithelium cells that remain after 
teeth erupt and they still possess the potential to proliferate and differentiate (35-39). 
They are believed to be responsible for the development of several epithelial odontogenic 
cysts and tumors such as ameloblastoma (1, 40).  
 
 
 
 
 
 
 
 
 
Figure 1.2 Enamel epithelium remnants: origin of odontogenic tumor. After tooth 
formation is completed, enamel epitheliums are left in the periodontal ligament area and 
potentially give rise to odontogenic tumor. (a) Tumor forming in the mouse incisor 
(circled) initiated from enamel epithelium remnants at the root area. (b) Hertwig´s 
epithelial root sheath leaves epithelial cells in the periodontal ligament area after tooth 
genesis. Modified from (1). 
 
 
Ameloblastoma 
 Ameloblastoma, a usually benign but locally invasive tumor, is the most common 
odontogenic neoplasm derived from odontogenic epithelium. It has a high recurrence 
rate, persistent growth with the high ability to produce marked deformity of the face, but 
rarely becomes malignant. The term “ameloblastoma” is derived from the histology of 
the tumor that resembles the developing tooth germ. Ameloblastoma tends to recapitulate 
the incomplete events that occur during normal tooth formation (40, 41). It exhibits soft 
a b 
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tissue of the enamel organ and contains a mixture of tooth elements. For instance, one 
important feature of ameloblastoma is the island of odontogenic epithelium with the 
polarized cuboidal or columnar cells around the loosely angled shaped cells in a pattern 
similar to ameloblasts and stellate reticulum. In some cases, enamel matrix proteins are 
enumerated and can be found in the lesions.  
 
Clinical features and tumor behavior 
 Ameloblastomas occur over a wide range of ages from children to the elderly. Due 
to the slow growing nature of this tumor, patients are usually diagnosed in the fourth and 
fifth decades of life. Gender predilection is still controversial. Ameloblastoma has a 
higher incidence in Asian populations (42-46). In particular, ameloblastoma is more 
commonly encountered in Africans, where it accounts for about 60% of odontogenic 
tumors (33). The frequency of ameloblastoma is rare in Caucasians representing about 
11% of odontogenic tumors. Not surprisingly, it is more common in African-Americans 
(33). The most prevalent location of ameloblastoma is the mandible (80%), of which 70% 
occur in the molar region. In the maxilla, most lesions also arise in the molar area. 
Ameloblastoma is a slow growing tumor and may be asymptomatic in the early 
stages of tumor development. In advanced stages, patients may present with swelling of 
the jaw bone and become aware of marked facial disfigurement. The enlargement of 
these tumors is usually confined in bone, but in advanced cases, bony perforation and soft 
tissue overgrowth can be found due to the extensive destruction of overlying bone. In the 
maxilla, minor bony expansion can be observed since the lesion can protrude into sinus 
spaces. Adjacent teeth usually become loosened and resorption of roots is common, but 
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rarely painful. Ameloblastoma has a high recurrence rate (50-90%), therefore surgical 
resection with a margin of normal bone is the preferred treatment. 
 
Histopathology 
Ameloblastomas can be classified according to their histological patterns as 
follicular, plexiform, granular cell, acanthomatous, desmoplastic and basal cell types 
(40). The follicular and plexiform types are the most common patterns and in some 
tumors the mix of both patterns exists. No consistent differences in terms of tumor 
behavior have been found among the different histological types (33, 41). In the follicular 
pattern (Figure 1.3, right), epithelial islands form around nests or follicles which 
resemble the enamel organ of developing teeth. Each follicle is occupied by stellate-
reticulum like cells in the center surrounded by a single layer of reverse polarized 
ameloblast-like cells. In the plexiform type (Figure 1.3, left), tumor epithelium forms a 
network of interconnected strands. Each epithelium strand contains the same components 
as in the follicular pattern, thus each strand is connected by ameloblast-like cells that 
encircle the stellate reticulum-like cells. In some cases, stellate-reticulum like cells can be 
located outside of the epithelium strands.  
Minor variations of other histological types include the acanthomatous type where 
the odontogenic epithelium exhibits squamous differentiation. The granular cell type is 
characterized by cells that have abundant granular eosinophilic cytoplasm in the tumor 
nests. The desmoplastic type demonstrates a high content of collagenized stroma that 
supports the tumor. The uncommon basal cell type contains nests of basaloid cells similar 
to basal cell carcinoma. 
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Figure 1.3 Histology of ameloblastoma. The plexiform and follicular patterns are the 
most common histological subtypes of ameloblastoma. Plexiform ameloblastoma shows 
the network of interconnected epithelium strands (Left). Follicular ameloblastoma shows 
the peripheral cuboidal/columnar cells and central stellate-reticulum like cells (Right). 
 
 
Subtypes of ameloblastoma (41) 
According to the new classification of head and neck tumors by World Health 
Organization in July 2005 (34), ameloblastoma is categorized in relation to age, 
distribution, localization, radioimaging features, and prognosis to four variants, 
solid/multicystic ameloblastoma, extraosseous/peripheral ameloblastoma, desmoplastic 
ameloblastoma and unicystic ameloblastoma. 
 In an analysis of the international literature, 3,677 cases of ameloblastoma were 
reviewed, of which 92% were solid or multicystic, 6% were unicystic, and 2% were 
peripheral (47). 
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Solid or multicystic ameloblastoma   
The solid or multicystic variant of the ameloblastoma occurs in patients over a 
wide age range being more common in the third through seventh decade of life (48, 49).
 
The most common radiographic feature is a multilocular radiolucency with cortical bone 
expansion. All histological patterns of ameloblastoma, follicular, plexiform, granular cell, 
acanthomatous, desmoplastic and basal cell types, can present as multicystic 
ameloblastoma.   
 
Unicystic ameloblastoma   
The unicystic type of ameloblastoma is most commonly seen in young patients, 
with about 50% of these tumors being diagnosed during the second decade of life (47). 
The most common radiographic presentation for the unicystic ameloblastoma is a well-
defined unilocular radiolucency, usually associated with an unerupted tooth. 
Histologically, three variants of unicystic ameloblastoma are presented. Luminal 
unicystic ameloblastoma is a cyst lined by ameloblastic epithelium. The intraluminal 
unicystic ameloblastoma contains a localized nodular proliferation of ameloblastoma 
tissue into the cystic lumen. These nodules usually exhibit a typical plexiform pattern of 
ameloblastoma. A third variant is described as mural unicystic ameloblastoma where 
ameloblastic tissue infiltrates the fibrous wall of the cyst. This type is important to 
distinguish because the extent and depth of the ameloblastic infiltration of the tumor 
influences considerably the treatment procedure.  
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Peripheral ameloblastoma 
This rare type of ameloblastoma usually occurs over a wide range of ages. The 
clinical presentation of peripheral or extraosseous ameloblastoma is a non-ulcerated 
sessile or pedunculated gingival lesion. The origin of this variant could be the rests of 
dental lamina or the basal cell of the surface epithelium (50). 
 
Desmoplastic ameloblastoma (51-53) 
Desmoplastic ameloblastoma is a rare variant that presents with several different 
characteristics from typical ameloblastoma. From the review of case reports (51, 53), the 
majority of these tumors are located at the anterior or premolar region of the jaws. 
Moreover, half of the lesions occur in the maxilla which is in contrast to the other forms 
of ameloblastomas that favor the mandibular molar area. Histological appearance of 
desmoplastic ameloblastoma is also different. This tumor exhibits small nests and/or 
strands of odontogenic epithelium that are separated by dense fibrous connective tissue 
(stromal desmoplasia) (52, 54, 55). Columnar or cuboidal cells with reverse polarity that 
resemble ameloblast cells can be seen in the lesion but are not the dominant feature. 
However, age and gender prevalence are similar to those found with other variants of 
ameloblastoma. 
 
Treatment and prognosis 
Treatment of ameloblastoma continues to be controversial due to the benign but 
locally aggressive nature of the tumor. Although aggressive surgical excision treatment is 
generally accepted as the most reliable and necessary approach, these tumors still 
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frequently recur. Recurrence rates of ameloblastoma are reportedly as high as 15% to 
25% after radical excision treatment (56-59) and 75% to 90% after conservative excision 
treatment (57, 60, 61). Numerous treatments have been suggested for ameloblastoma 
depending on several factors such as, type of tumor, location, extent of disease, 
histological type, radiographic presentation as well as patient age. Treatments range from 
simple enucleation with bone curettage (62, 63) to radical resection (64). Unicystic 
ameloblastoma is well localized by the fibrous capsule of the cyst and can be curable by a 
conservative approach. The mural unicystic ameloblastoma where ameloblastic tissue 
infiltrates the fibrous wall of the cyst requires treatment with radical surgery. Multicystic 
ameloblastoma has more invasive characteristics and typically infiltrates the adjacent 
tissue and the cancellous space; a multicystic ameloblastoma therefore must be treated by 
wide resection of the jaw (65, 66). Malignant transformation of ameloblastoma is very 
rare, but may be classified as metastasizing ameloblastoma or the more aggressive 
ameloblastic carcinoma (67). 
While ameloblastoma is likely curable after radical resection and when all soft 
and hard tissue margins are histological negative, recurrence can still occur in some 
cases.  Several studies have tried to identify indicators to predict for recurrence of this 
tumor. Recurrent ameloblastoma is associated with high numbers of proliferating cell 
nuclear antigen (PCNA) positive cells compared with the primary tumors
 
(68). Solid 
multicystic ameloblastoma also has more nuclear PCNA positive cells compared with the 
unicystic ameloblastoma that is less aggressive in behavior
 
(68, 69). Other molecules 
involved in cell cycle, such as highly expressed BCL2 and BCLX, are reported to support 
the aggressive behavior of these ameloblastomas
 
(70, 71). Unfortunately, there are no 
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radiological, histological or molecular markers known to predict with reliability the 
recurrence tendency of ameloblastoma.  
 
Molecular pathology 
 The molecular determinants driving initiation and maintenance of ameloblastomas 
and other odontogenic tumors remain unclear. The investigation and systematic study of 
the molecular mechanisms operating in these tumors is scarce due to the lack of 
appropriate cell culture and/or animal models. However, there is evidence from gene and 
protein expression studies that suggest alteration in signaling pathways that play a role 
during normal tooth development. It therefore seems likely that TNF, FGF, SHH and 
WNT pathways might contribute to the etiology of odontogenic tumor (72-75). There is 
no known genetic mutation related with pathogenesis of ameloblastoma. Studies have 
shown that TNFα can induce cell survival and proliferation in ameloblastoma cells, AM-
1, through AKT and p44/42 mitogen activated protein kinase (MAPK) activation (76, 
77). BCL2 and BCLX are reported to support ameloblastoma cell survival by inhibition of 
apoptosis (70, 71). Aberrant expressions in both canonical and non-canonical WNT 
pathways such as WNT1, β-catenin and WNT5A, are found in ameloblastoma as well 
(78-81), however the molecular details of how alteration in WNT signaling or other 
pathways affect the tumorigenic behavior of enamel epithelium have not been studied. 
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Characteristic of tumorigenic cell (82) 
Transformation of normal cells into tumorigenic cells is a multistep process that 
requires several alterations in cell behavior. Most tumorigenic cells share six essential 
changes in behavior that are self-sufficiency in growth signals, insensitivity to anti-
growth signals, avoidance of programmed cell death, limitless cell replication, induced 
angiogenesis, invasion and metastasis (82). These processes can occur at different time 
points during tumorigenesis and they are mostly governed by mutations in anti-cancer 
defense mechanisms that lead to chromosome instability and accumulation of mutations 
(82). 
 
Proliferation 
Eukaryotic cell proliferation involves the progression through cell cycle. It 
consists of the following phases: G1 phase is the phase that cells enter after mitosis. At 
this stage, most cells leave the cell cycle and remain in the resting stage in a non-
proliferative G0 phase. After receiving growth stimuli, cells can reenter the G1 phase and 
prepare for cell division. Next is the synthetic, S, phase where DNA is duplicated and 
preparation for cell division proceeds in the subsequent G2 phase. The final step in the 
cell cycle is mitotic, M, phase, where the parental cell and its duplicated chromosomes 
segregate into two daughter cells in G1 phase. Cell cycle is tightly regulated by a number 
of proteins that control the entry and exit of cells from different phases of the cell cycle. 
The most important “checkpoints” in the cell cycle occur at the late G1 phase and the late 
G2 phase where the accuracy of the genome is crucial. The major regulators of cell cycle 
are cyclin/cyclin dependent kinase (CDKs) complexes. Together with cyclins, CDKs play 
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an important role in phosphorylation and inactivation of the growth-inhibitory protein, 
retinoblastoma (pRb) (83). pRb induces regulation of the E2F transcription factor and is 
important for preventing cells in G1 phase from entering S phase, therefore deactivation 
of pRb results in increasing cell proliferation. 
Many cancer cells have the ability to stimulate their own proliferation via the 
production of their own growth signals, activating mitogenic signals and deactivating the 
growth-inhibitor signals. Common mitogenic signals that are known to regulate cell cycle 
proteins for example; Ras/Raf/MAPK pathway, C-MYC and β-catenin are frequently 
upregulated in several types of cancer (84-86). Loss of growth inhibitory or tumor 
suppressor signals, such as p53 and p21, are often found and mostly involved in 
subsequent deactivation of pRb (87). 
 
Limitless of cell replication 
Normal cells possess a certain potential for the number of cell replications. After 
reaching the limit of doublings, they enter the state called senescence. This process is 
governed by the mechanism that shortens the ends of the chromosome, the telomeres. 
During each cell cycle, cells lose about 50-100 bp of telomeric DNA and this progressive 
shortening eventually prevents further replication of the chromosomes and results in the 
death of the cells (88). 
Telomere maintenance is a key to limitless replication of tumorigenic cells. The 
chromosome end is protected by the enzyme “telomerase” which adds hexanucleotide 
repeats onto the ends of telomeric DNA (89). Upregulation of telomerase in tumors helps 
to protect the chromosome in the remaining part of the tumors by the mechanism called 
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alternative lengthening of the telomeres. Telomeres are thus protected at a length above a 
critical threshold, allowing unlimited replication potential of tumorigenic cells (90).  
 
Apoptosis 
Apoptosis is a mechanism of cell death that serves as an intrinsic protection 
system to eliminate unwanted or harmed cells from the body. Most tumorigenic cells 
acquire the ability to evade apoptosis to undergo malignant transformation (91). The 
process of apoptosis begins with the condensation and fragmentation of DNA, followed 
by cell shrinkage, membrane blebbing, and eventually phagocytosis of the remaining 
apoptotic bodies. In contrast to necrosis induced cell death, apoptosis occurs without 
inducing inflammation (92). Apoptosis can proceed via two different pathways. The first 
pathway involves the series of cleavage induced activations of several different proteases 
called caspases. A second pathway occurs in a caspase independent manner through the 
activation of proteases like cathepsins and calpains (93). Apoptosis can be induced by 
extrinsic and intrinsic stimuli, such as activation of the death receptors FAS and TNFs, 
oncogenic stress, hypoxia and ultraviolet (UV) irradiation (94). In response to cellular 
stress, p53, a tumor suppressor, is a key molecule in initiating apoptosis. Activated p53 is 
accumulated in the nucleus and triggers irreversible cell cycle arrest and apoptosis (95). 
p53 mutations are frequently observed in cancer cells. Another means for tumorigenic 
cells to escape apoptosis is via deactivation of pro-apoptotic proteins such as caspases, 
FLICE inhibitory protein, and the human BCL2 family, and/or upregulation of survival 
genes like the phosphatidyl inositol 3 kinase (PI3K) pathway (96). 
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Sustained angiogenesis 
The ability to induce and maintain angiogenesis is necessary for the growth of 
tumors. New blood vessels provide oxygen and nutrients, and also take away metabolic 
waste products from tumors. Moreover, tumor proliferation is stimulated by abundant 
growth factors, such as FGFs, granulocyte colony-stimulating factors, and platelet-
derived growth factor (PDGF), which are produced by vascular endothelial cells. One 
mechanism allowing tumors to acquire neovascularization is via the change in balance 
between angiogenesis inducers and inhibitors (97). Vascular endothelial growth factor 
(VEGF) and FGFs are common angiogenesis inducers and their expressions are 
upregulated in many cancers, whereas angiogenesis inhibitors such as thrombospondin-1 
or β-interferon are downregulated (98). Notably, the amount of angiogenesis is related to 
metastasis and prognosis of cancers (99), therefore tumor angiogenesis offers a promising 
target for cancer therapy. 
 
Metastasis 
Although metastasis is a very rare event for odontogenic tumors, it can be 
observed in untreated or recurrent ameloblastoma (67). The metastatic process occurs 
through the following steps; loss of adhesion from primary tumor, breakdown of the 
extracellular matrices (ECM), cell migration into the blood or lymphatic vessels, 
transportation in the circulation, adhesion and migration out of vessels and establishing a 
tumor in a new environment.  
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Cell adhesion 
Several classes of proteins involved in cell adhesion are altered in invasive or 
metastatic cells. Epithelial cells normally adhere to each other via diverse structures, such 
as tight junctions, adherens junction and desmosomes (100).  They are also attached to 
ECM via the cell-matrix adhesion receptors called integrins. Integrins exist as 
heterodimers of α and β subunits that give rise to at least 24 different heterodimers, each 
of which can bind to specific ECM ligands (101). Activation of integrins plays an 
important role in cell adhesion and migration. Upon binding to ECM ligands, cytoplasmic 
tails of integrins sequester a range of proteins to form focal adhesion complexes at the 
ECM/integrin junction. Actin cytoskeleton-binding proteins, tensin and talin then bind to 
the cytoplasmic tail of integrins and thereby link the cytoskeleton to the focal adhesions 
(101). 
Another important group of cell adhesion proteins is the cell-cell adhesion 
molecules and some of the most important proteins in that context are cadherins (E, N 
and H-cadherins) and selectins (E, L and P-selectins) families. These molecules are 
responsible for cell-cell adhesion and also for intravasation and extravasation of tumor 
cells. It is noteworthy that, loss of cell adhesion, especially repression of E-cadherin, 
indicates the events of epithelial-mesenchymal transition (EMT) and results in the 
initiation of cancer metastasis (102). 
 
Extracellular matrix degradation 
The ability to degrade ECM is critical for tumor cell invasion and metastasis. The 
ECM degradation process involves the regulation of extracellular proteases (103, 104). 
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Increased expression of protease genes and/or downregulation of protease inhibitors are 
associated with tumor cell invasion (105).  Expression of ECM proteases can be regulated 
by several stimuli, for example epidermal growth factor, PDGF, TNF-α and interleukin 1 
are reportedly inducing ECM protease production (106). The matixmetalloprotease 
family (MMPs) is believed to play an essential role in tumor invasion and metastasis 
since they are important for angiogenesis and cell migration.(107, 108) 
 
Cell migration 
 Cell migration is a cyclical process that involves the dynamic of actin 
reorganization and ECM adhesion. Cell motility is a result of actin polymerization that 
leads to cell membrane protrusion at its front and retraction at its rear (109). Formation 
and disassembly of focal adhesion are keys of cell migration. Focal adhesion synthesis 
leads to the activation of several signaling molecules, for examples focal adhesion kinase 
(FAK), SRC, PI3K, and the RHO GTPases (109), consequently generate mechanical 
force for cell movement by inducing the interaction between myosin II and actin 
filaments (110). 
 
Actin cytoskeleton reorganization 
Actin is a cytoskeleton filament that plays a major role in controlling cell 
movement (109). Constant polymerization and remodeling of actin fibers is necessary for 
membrane protrusion at the cell’s leading edge, which causes the cell to move forward, 
and allows the formation of the retractile stress fibers that are required for contraction of 
the cell at trailing edge (111). Actin polymerization occurs by the continuous addition of 
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actin monomers to the plus end until the elongation is ceased by the binding of actin 
capping proteins such as gelsolin to that end (109). On the minus end of actin filament, 
disassembly of actin monomers is controlled by cofilin (112). Two major structures of 
membrane protrusion can be found in motile cells, lamellipodia refers to a broad, flat and 
lattice-like membrane extension, whereas filopodia is thin, cylindrical and bundled in 
shape (113). Another major protein important in cell migration is myosin II. Adenosine 
triphosphate (ATP) hydrolysis by myosin II causes conformational change that allows 
myosin to move along and bind to actin filaments, therefore myosin II acts as a mechano-
chemical enzyme that generates energy for cell movement from ATP hydrolysis (114). 
 
The Rho family 
The Rho family of small guanosine triphosphate (GTP)-binding proteins is known 
to be responsible for cell migration in many cell types. The Rho family is comprised of 
RHO (RHOA, B and C), RAC (RAC1, 2 and 3) and CDC42 that all play important roles 
in regulating cell movement at specific sites. At the leading edge of migrating cells, 
activation of RAC and CDC42 is required for lamellipodia and filopodia formation 
respectively (113), while activation of RHO is critical for cell contraction at the trailing 
edge (115). Like other proteins in the GTPase family, RHO GTPases exist in the dynamic 
active GTP-bound and inactive guanosine diphosphate (GDP)-bound forms. The cycle of 
RHO GTPase is regulated by: the guanine nucleotide exchange factors (GEFs) that 
facilitate the GDP-to-GTP exchange, the GTPase-activating proteins (GAPs) that enable 
hydrolyzation of GTP to GDP, and the GDP dissociation inhibitors (GDIs) that bind to 
the inactive form of RHO GTPases and inhibit the GDP-to-GTP exchange (115). 
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Focal adhesion kinase 
The formation of new focal contact at the front end and cell adhesion disassembly 
at the rear end are fundamentals of cell migration. The rate of migration is determined by 
the strength and stability of focal adhesion (110, 116). Focal adhesion turnover is 
regulated by a tyrosine kinase called FAK. Focal contacts that are formed at the ECM-
integrin junction activate the assembly of intracellular focal adhesion complexes and the 
recruitment of actin cytoskeleton together with several signaling molecules. This 
provides a link between focal adhesion complexes and the cytoskeleton (117). FAK is 
also important for activation of RAC and CDC42 (118, 119). An abundance of proteins 
participate in cell migration. For instance, β-actin, p130CAS and paxilin, are substrates 
for FAK phosphorylation. FAK itself can trigger cell proliferation by recruiting the 
adapter protein GRB2 that leads to activation of RAS (120). 
 
The WNT family and WNT signaling pathways 
The WNT family constitutes one of the major developmentally significant groups 
of signaling molecules that control a variety of processes such as cell fate specification, 
cell proliferation and differentiation, cell polarity, cell adhesion, cell migration, and cell 
death (121-124). All WNT proteins share the similar structure of 39-46 kD lipid-modified 
secretory glycoproteins containing 350-400 amino acids, with a highly conserved pattern 
of 23-24 cysteine residues and several asparagines-linked glycosylation sites (123). 
Conserved cysteine residues serve as the sites for palmitoylation, lipid modification 
which is critical for WNT protein function (125). The founding member of the WNT 
family is mouse Wnt1 and Drosophila wingless (wg) (126). Orthologs of Wnt1 and wg are 
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conserved among species and have been found in many organisms from C. elegans to 
human, with each organism possessing multiple related Wnt genes (127). At least 
nineteen WNT proteins have been identified in vertebrates to date (128).  
WNT proteins are generally classified into two functional classes; the WNT1 
class and the WNT5A class. The WNT1 class includes the inducers of a secondary body 
axis in Xenopus which are WNT1, WNT2, WNT3, WNT3A, WNT8A and WNT8B. 
Interaction by WNT proteins of this class to their receptors ultimately leads to the 
activation of the canonical WNT/β-catenin pathway (128). The WNT5A class includes 
WNT4, WNT5A, WNT5B, WNT6, WNT7A and WNT11 that do not induce secondary 
axis formation in Xenopus. The WNT5A class proteins interact with their receptors 
resulting in activation of several alternative downstream pathways, involving increasing 
intracellular calcium levels (128).  However, recent evidence shows that WNT proteins 
can generate distinct physiological responses by triggering various intracellular pathways 
depending on the receptors and other contexts that present at the cell surface (129-131). 
After WNT proteins are secreted, their activity can be modulated by a variety of 
regulators. In vertebrates, WNT antagonists, such as secreted frizzled-related protein and 
WNT inhibitory factor, directly bind to WNT protein and prevent the interaction of WNT 
proteins to their receptors (132, 133). Another potent WNT inhibitor is dickkopf (DKK). 
The mechanism of DKK inhibitory function is unclear but is likely due to the ability of 
DKK to bind to WNT co-receptors and induced co-receptor internalization (123).  
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Receptors and coreceptors in WNT pathway (127, 128) 
 Different WNT proteins initiate the various cellular responses due to the 
repertoire of receptors at the cell surface. The major receptors of the WNT ligands are 
Frizzleds (FZDs). Several members of the FZD family have been identified in many 
organisms with each organism possessing multiple Fzd genes. Fzd genes encode seven-
transmembrane, G-protein-coupled proteins (134, 135) containing a cysteine-rich domain 
(CRD) at the amino-terminal that binds WNT protein with high affinity (136). A single 
WNT protein can bind to a combination of FZDs, including FZD homologs from 
different species (137, 138). Binding of WNT protein to FZD activates either the 
canonical or non-canonical WNT signaling pathway leading to specific biological 
functions. FZD2, FZD4 and FZD5 have been shown to be the receptor for WNT5A and 
can initiate diverse signaling pathways and cellular responses (131, 139-141). 
In addition to FZDs, other co-receptors are necessary for the WNT signaling 
pathway. The binding of WNT ligands to Low density lipoprotein receptor-related 
protein5/6 (LRP5/6), a singlepass transmembrane receptor, is also required for activation 
of the canonical WNT signaling pathway (142, 143). Recently, other co-receptors for the 
WNT signaling pathway have been identified. RYK (receptor-like tyrosine kinase) 
belongs to the receptor tyrosine kinase family shown to regulate both canonical and non-
canonical WNT signaling pathways via an unclear mechanism (144, 145). ROR2 
(receptor tyrosine kinase like orphan receptor 2) is an orphan tyrosine kinase receptor that 
contains an extracellular CRD. Mouse ROR2 has been shown to be the alternative 
receptor for non-canonical WNT5A/JNK signaling involved in cell migration and cell 
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adhesion (146, 147). ROR2 is also necessary for mediating WNT5A antagonist effects on 
the canonical WNT signaling pathway (131). 
 
The canonical WNT/β-catenin signaling pathway  
The majority of WNT proteins including WNT1, WNT3A, and WNT8 activate 
downstream target gene expression by the transcriptional factor, β-catenin. In the absence 
of WNT protein, β-catenin in the cytoplasm is associated with the destruction complex of 
glycogen synthase kinase-3β (GSK-3β), axin and adenomatous polyposis coli (APC). β-
catenin is subsequently phosphorylated at the conserved serine and threonine residues in 
the amino-terminal region by casein kinase 1 (CK1) and GSK-3β. These phosphoamino 
acids serve as the active sites for β-transducin-repeat-containing protein (β-TrCP) /Slimb, 
a component of the supercoiling factor ubiquitin ligase complex. β-TrCP/Slimb 
polyubiquitinates and targets β–catenin to degradation by proteasome. As a result, β-
catenin in the cytoplasm cannot translocate into the nucleus and the transcription of Wnt 
target genes is silenced (148, 149). 
In the presence of WNT protein, the binding of WNT ligand to FZD results in the 
formation of a WNT-FZD-LRP5/6 complex. This interaction is followed by recruitment 
and phosphorylation of dishevelled (DSH) that subsequently binds and inhibits GSK-3β 
activity (150, 151). In addition, DSH also recruits axin to the cell membrane where it 
binds to WNT-FZD-LRP5/6 complex and promotes axin degradation (152). Without the 
formation of the destruction complex, phosphorylation of β-catenin and its degradation 
are impaired. The accumulating β-catenin in cytoplasm then translocates to the nucleus. 
In the nucleus, the T cell factor (TCF) and LEF are associated with transcriptional 
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repressors, such as groucho, at the promoter region of WNT target gene. β-catenin 
activates TCF/LEF by displacing the transcriptional repressor and forming a complex 
with TCF/LEF (150, 153-155). This leads to the transcription of a variety of WNT target 
genes that play important roles for regulating cell fate, proliferation, differentiation, 
adhesion and survival such as c-Myc (156), Cyclin D1 (157-159), Cyclooxygenase 2, Vegf 
and Axin-2 (160, 161). 
 
The non-canonical WNT signaling pathway 
In the non-canonical WNT signaling pathway, the WNT5A class of proteins 
consists of WNT4, WNT5A, and WNT11 that function through a non β-catenin-
dependent fashion, such as the planar cell polarity (PCP) pathway (157, 162-164) and the 
WNT calcium-dependent pathway (165, 166). However, the signaling mechanism in the 
non-canonical WNT pathway remains unclear.  
 
WNT/calcium pathway 
In the WNT/calcium pathway, binding of WNT5A to FZD receptors, especially 
FZD2, leads to several cellular mechanisms that involve increased intracellular calcium 
release. Several enzymes in the calcium signaling pathway including calcium 
calmodulin-dependent protein kinase II (CAMKII) or calcineurin (CaCN) and protein 
kinase C (PKC) are activated in WNT/calcium pathway (139, 166-168). Studies have 
shown that WNT5A activates protein kinase G and phosphodiesterases that in turn leads 
to a sharp decrease in cyclic guanosine monophosphate levels (169, 170). The mechanism 
of intracellular calcium release is believed to occur via stimulation of Gαo and Gαt2 in 
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the G-protein dependent signaling pathway (169, 171). As a result, phospholipase Cβ is 
activated and translocated to the cell membrane, where the second messengers inositol 
trisphosphate (IP3) and diacylglycerol (DAG) are generated (165, 172). IP3 then interacts 
with the sarco/endoplasmic reticulum calcium transporting ATPase pump at the 
endoplasmic reticulum membrane and induces the release of calcium, whereas DAG 
activates PKC. These processes have been shown to subsequently stimulate the nuclear 
factor of activated
 
T cells (NFAT) transcriptional factors (173-175). WNT/calcium 
signaling has been observed in zebrafish embryos (165, 176, 177), mouse cells (169, 
178), and in thyroid carcinoma cells (179). In addition, FZD3, -4, -5, and -6 are also 
known to mediate PKC activation (167, 168). 
 
WNT/PCP pathway 
WNT5A/PCP signaling is regulated by PDZ and DEP, the two conserved domains 
of DSH (180-182). Recruitment of DSH leads to activation of JNK (183, 184), a member 
of MAPKs family that is primarily responsive to environmental stress and cytokines 
(185). Engagement of DSH by WNT5A also involves the activation of RHOA/RAC 
small GTPase (182) and RHO-associated kinase, ROCK, (186, 187), which in turn leads 
to the regulation of cytoskeletal organization, as well as activation of JNK (180, 186). 
JNK phosphorylates C-JUN and activates transcriptional factor AP-1. However, the 
requirement of DSH and RHO GTPases on JNK activation is still controversial (183). 
The WNT/PCP pathway is essential in epithelial cell polarity of Drosophila and 
convergent extension movement during gastrulation of vertebrates (188). 
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Interaction between non-canonical and canonical WNT pathway 
In addition to WNT5A activity through the non-canonical WNT signaling 
pathway, several studies have shown that non-canonical WNT5A signals can interact 
with the canonical WNT/β-catenin pathway in a variety of ways (139, 189). WNT5A 
activates nemo-like kinase (NLK) through CAMKII and in turn suppresses the 
transcriptional activity of TCF/LEF by inducing phosphorylation (139, 188, 190, 191). In 
addition, binding of WNT5A to ROR2 initiates RHO GTPase-independent activation of 
JNK that can inhibit the canonical WNT pathway (188). WNT5A also can promote β-
catenin degradation in a GSK-3 β-independent fashion by increasing expression of Siah2 
(190). 
Although it appears that particular WNT proteins preferentially stimulate the 
canonical or non-canonical pathways, the distinction is not absolute. WNT signaling 
specificity may be achieved, in part, by the combination of the cell surface receptor and 
intracellular context that differs from cell type to cell type (192, 193). Recently, WNT5A 
has been shown to activate or inhibit the canonical WNT signaling pathway depending on 
the expression of appropriate FZD receptors and the co-receptors. In the presence of 
FZD4 and LRP5, WNT5A can activate canonical WNT signaling pathway. On the other 
hand, WNT5A antagonizes canonical WNT signaling when ROR2 is available (131). The 
WNT5A/PCP cascade is also known to stabilize β-catenin (194). Moreover, C-JUN, a 
downstream target of the non-canonical pathway, is found to act synergistically with 
TCF/LEF to promote gene transcription in intestinal cancer (195). Evidently, WNT5A 
signals are complex and closely cross-linked. These findings support the model that 
signaling by WNT5A can be dictated by the availability of cell receptors and therefore 
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generate a variety of cellular responses. This ability of WNT5A to switch between two 
different forms of signaling is particularly interesting given that WNT5A has been 
considered as both a tumor suppressor and an oncogene in various cell types (196-198). 
Further study into the details of these mechanisms is needed to better understand the 
complexities of Wnt5a signaling and how WNT5A contributes to tumorigenesis. 
 
Figure 1.4 Schematic illustrations of the non-canonical WNT5A signaling pathways. 
WNT5A can initiate several downstream signaling pathways depending on cell surface 
receptors and intracellular contexts. These pathways include WNT5A/calcium, 
WNT5A/PCP and WNT5A antagonized Wnt/β-catenin pathways. Modified from (188). 
 
 
 
WNT5A: structure and expression during embryogenic development 
The first Wnt5a gene was identified in the mouse where its temporal expression 
correlates with tissue patterning and morphogenesis (199). Orthologs of Wnt5a have also 
been found in other species such as drosophila, frog and zebrafish where their 
expressions are developmentally regulated. In humans, molecular cloning and sequencing 
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of WNT5A revealed cDNAs approximately 5.8 kb in length, encoding the mature protein 
that contains 380 amino acid residues. Human WNT5A shares over 93% homology to the 
reported sequences of WNT5A proteins from other species. WNT5A maintains a 
characteristic of the WNT protein family that posseses a hydrophobic signal sequence 
(CKCHGvSGSC), 24 conserved cysteine residues, 4 asparagine-linked oligosaccharide 
consensus sequences, and a tyrosine sulfation site (199). Due to the chemical structure, 
the majority of secreted WNT5A is bound to heparin sulfate proteoglycans present in the 
ECM (200). This chemical linkage greatly influences the WNT5A gradient needed, 
especially for cell polarity, cell movement and tissue patterning.  
The primary regions of human WNT5A and mouse Wnt5a expression are the sites 
just prior to tissue differentiation and patterning. In mouse, Wnt5a is present in the distal 
compartments of several organs such as the central nervous system, limb, craniofacial 
processes, genitals and outer ear (147). The Wnt5a expression in differentiating cells is 
maintained over a period of time and finally diminishes at the terminal differentiation 
stage (201). WNT5A null mice exhibit perinatal lethality from defects in lung 
development and fail to develop multiple structures from the primary body axis, 
mandible, head and tongue. Interestingly, this defect in morphogenesis is due to a 
reduced rate of cell proliferation in tissue of the outgrowing structures (147) suggesting 
the indispensable nature of WNT5A during tissue development. 
 
WNT5A signaling during tooth development 
Several lines of evidence suggest an essential role of WNT signaling during tooth 
formation, especially on epithelial development (202, 203). Molecules in the WNT 
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signaling pathway show reiterative and overlapping expression during tooth 
development, mostly in the epithelial components (41). In mice, Wnt4 and Wnt6 are 
expressed in the facial, oral and dental epithelium. Wnt10b is localized to the presumptive 
dental epithelium. Wnt3 shows restricted expression in the enamel knots (204). 
Furthermore, over- and ectopic expression of WNT3 in the epithelial compartment of 
postnatal lower incisor teeth causes progressive loss of ameloblasts and enamel in 
transgenic mice (205), supporting the role of WNT signal in regulating enamel epithelial 
development. Inhibition of WNT signaling either by blocking the WNT co-receptor or 
knockdown the LEF-1, nuclear mediator of WNT signal, results in the absence of all 
teeth in mice (206, 207). In LEF-1 null mice, tooth development is arrested at the bud 
stage (208) while overexpression of LEF-1 in epithelial cells in transgenic mice leads to 
an increased enamel epithelium and formation of tooth like structure (209).  
Unlike other WNT proteins, studies have shown that Wnt5a expression is 
specifically found in dental mesenchyme during the early stages of mouse tooth 
development while its expression cannot be detected in the enamel epithelium (204, 210). 
The function of WNT5A during tooth development is largely unknown. However, the 
role of WNT5A in dental mesenchyme differentiation is speculative since WNT5A is 
known to counteract WNT canonical signaling and the WNT/β-catenin pathway is known 
to inhibit dental pulp stem cell differentiation (211). 
 
Effects of WNT5A on cell behaviors 
In the past, WNT5A has been defined as a non-transforming WNT protein due to 
the lack of transforming activity on mouse mammary epithelial cells (212, 213). WNT5A 
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has also been shown to reverse cell transformation (214, 215) and exhibit tumor 
suppressor activities in some studies (197, 216, 217). The role of WNT5A is still 
controversial, but in fact there is a multitude of evidence suggesting that WNT5A plays 
essential roles in cancer, especially in tumor progression (188). WNT5A can promote cell 
proliferation of progenitor cells (147, 218, 219), glioma cells (220), vascular endothelial 
cells (221) and several types of cancer cell (188, 222). Additionally, studies show that 
WNT5A also promotes cell growth and survival by inhibiting apoptosis in osteoblast 
(223) and vascular endothelial cells (221). Furthermore, forced expression of WNT5A in 
the deeper skin induces changes in the interfollicular epithelium mimicking true skin 
regeneration within the epithelial appendage, including formation of epithelia-lined cysts, 
sebaceous glands and hair follicles in the wound dermis (224). On the other hand, 
WNT5A suppresses cell proliferation in mammary epithelium, hematopoietic cell and 
lung (197, 213, 216, 217 ) or shows no effect on either apoptosis or cell proliferation in 
human mesenchymal stem cells and pituitary gland (225, 226). 
The effect on cell migration is another well-known function of WNT5A. WNT5A 
increases cell migration and/or invasion in fibroblasts (200,227), vascular endothelial 
cells (221), breast epithelial cells (228), gastric cancer cells (229), pancreatic cancer cells 
(222) and melanoma cells (168,227). Increased cell migration is an anticipated role of 
WNT5A when considering the putative role of WNT5A in promoting cell polarization 
and gastrulation during embryonic development (230). WNT5A enhanced cell migration 
is known to be activated through RHOA/RAC small GTPase (182) and ROCK (186, 
187), but a study in melanoma cell migration also suggests that WNT5A might signal via 
the PKC pathway and induce the loss of E-cadherin expression (231).WNT5A signals, 
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via ROR2, enhance migration in mouse embryonic fibroblasts by inducing filopodia 
formation and actin reorganization (227). WNT5A addition stimulates migration and 
invasion of NIH3T3 and L cells and is associated with an increased number of 
lamellipodia, activation of FAK and accelerated turnover of paxillin (229). In contrast, 
WNT5A has been found to suppress cell migration in breast epithelium (232), thyroid 
cell (179) and colon cancer cells (198).  
The effect of WNT5A on cell adhesion is believed to be one of the mechanisms 
whereby WNT5A modulates cell function and behavior. WNT5A modifies cell adhesion 
and migration of mammary epithelium cells by affecting collagen binding with the 
discoidin receptor I (232) and regulating stromelysin-I and mesothelin expression (233) 
which contributes to the alteration of normal phenotypes and function of the mammary 
epithelium cell. The connection between increased cell attachment by WNT5A and cell 
migration varies considerably. For example, WNT5A can increase cell adhesion and cell 
migration in fibroblasts and melanoma cells (168,200), but WNT5A enhanced cell 
adhesion in breast epithelial cell and myocyte is believed to suppress their migration 
(232, 234). 
Recently, the role of WNT5A in modulating the microenvironment has come into 
consideration. WNT5A increases production of MMP-1 in mouse mammary epithelial 
cells (233) and in endothelial cells (221). MMPs are well known for their essential role in 
ECM remodeling. WNT5A also promotes the formation of capillary networks by 
endothelial cells (221). Moreover, expression of WNT5A in melanoma is prominent at 
the edge of tumor invasion which strongly suggests a potential role of WNT5A in 
modifying tumor/stroma environment (188). 
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WNT5A expression and implication in cancers 
The roles of WNT5A are implicated in a variety of cancers. Aberrant WNT5A 
expression has been found to correlate with aggressive and malignant behaviors of cells; 
however function of WNT5A in tumorigenesis is obscure and contradictory. Several lines 
of evidence suggest that WNT5A posses oncogenic properties. WNT5A is overexpressed 
in malignant melanoma (168), gastric cancer, lung cancer (235), pancreatic cancer (222), 
and prostate cancer (236, 237). High levels of WNT5A expression correlated with the 
advanced stage and poor prognosis of these cancers with a more aggressive phenotype 
and metastasis. In melanoma, the expression of WNT5A is increased relative to skin and 
overexpression of WNT5A in melanoma cells directly causes actin reorganization and 
increased cell invasion (168). WNT5A signaling is essential for macrophage-induced 
invasiveness in breast cancer and has been shown to regulate breast cancer cell migration 
as well as proteolytic
 
activity of the macrophages (228). Furthermore, forced expression 
of WNT5A in the deeper mouse skin induces changes in the interfollicular epithelium, 
including formation of epithelia-lined cysts (188, 224). In addition, WNT5A was 
upregulated in astrocytoma and glioma (220), and WNT5A was found to be 
hypomethylated and overexpressed in 65% of prostate cancers (236). Interestingly, there 
is growing evidence suggesting that WNT5A is essential in tumor or malignant 
progression rather than in tumor initiation (188). In pancreatic cancer, WNT5A is 
upregulated in early pancreatic cancer genesis and the level is continuously increased 
during the progression from intraepithelial neoplasia to invasive adenocarcinoma (222). 
Moreover, WNT5A expression in squamous cell carcinoma and melanoma is associated 
with loss of E-cadherin and EMT which are the key events in metastasis (168, 238). 
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The opposite has also been reported. WNT5A has been considered as a tumor 
suppressor in some cancers, such as breast cancer, neuroblastoma, acute myeloid 
leukemia and primary dukes B colon cancer. In these tumors, the loss or reduction in 
WNT5A gene and protein expression correlated with aggressive phenotypes of cancer 
cells (196-198). WNT5A expression is downregulated in endometrial carcinoma cells 
(239) and pancreatic carcinoma (240) when compared with their normal cells of origin. 
WNT5A heterozygous mice developed chronic B cell lymphomas and it is noteworthy 
that WNT5A expression was lost in these malignant tissues (197). The tumor suppression 
mechanism of WNT5A is believed to be, in part, by interfering with the excess of 
canonical WNT/β-catenin signaling, particularly when it signals via CAMKII (188). In 
breast cancer, WNT5A expression is frequently reduced, which has been correlated with 
a higher incidence of early relapse and death (241). Notably, several other studies have 
examined the expression of WNT5A in breast cancer cell lines and tissues, but the results 
are contradictory (196, 242, 243). 
It is obvious that WNT5A signaling is very complex and can be modified by the 
multitude of regulating factors. Not only the availability of receptors, downstream 
effectors and inhibitors, but also the nature of cell types and interactions between cells 
and the microenvironment all can play a role in regulation and determine the complexity 
and outcome of WNT5A signaling. Taken together, this knowledge strongly suggests that 
WNT5A could be a promising target for cancer therapy. Inhibition of WNT5A signaling 
in ameloblastoma could possibly serve an effective therapeutic approach to preserve the 
jaw from radical excision treatment and prevent the recurrence of this tumor.
 CHAPTER II 
 
Hypothesis 
 
WNT5A modulates enamel epithelium tumorigenicity by promoting aggressive 
cell behavior via WNT5A/JNK pathway. 
 
 
 
 
 
 
 
 
 
 CHAPTER III 
STUDY I 
Characterization of WNT5A expression in normal and diseased enamel epithelium 
development 
 
Specific aims  
1. To characterize the temporal and spatial expression of WNT5A in normal and 
abnormal enamel epithelium. 
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INTRODUCTION 
There is ample evidence strongly supporting the important role of the canonical 
WNT signaling pathway during normal tooth development (202, 203). Studies show that 
several molecules in the WNT-β catenin pathway, such as WNT3 and LEF-1, are 
essential for regulating mouse enamel epithelial development (205-207). For the non-
canonical WNT5A signaling pathway, function of WNT5A during normal tooth 
formation has never been explored. Previous studies show that Wnt5a expression is 
specifically found in the dental mesenchyme during the early stages of normal mouse 
tooth development while its expression cannot be detected in the enamel epithelium (204, 
210). Additionally, WNT5A could also play a role during enamel epithelium 
tumorigenesis as high WNT5A protein expression is detected in granular cells in 
ameloblastomas (81). Interestingly, we also observed high WNT5A gene expression in 
epithelial components of ameloblastoma using the laser-microdissection-microarray 
approach (unpublished data). High WNT5A expression in ameloblastomas could 
contribute to abnormal phenotype and aggressive cell behaviors of the tumorigenic 
enamel epithelium. In this chapter, expression of WNT5A during normal and diseased 
(ameloblastoma) enamel epithelium development are characterized. Temporal and spatial 
WNT5A expression in ameloblastomas as well as during normal tooth development will 
provide the better understanding of the possible role of WNT5A in odontogenic tumors. 
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EXPERIMENTAL PROCEDURES 
Samples collection. Human and mouse tissue samples were obtained according to 
the Institutional Review Board and Institutional Animal Care and Use Committee 
approved protocols. First occurrence, multicystic/solid ameloblastoma tumors were 
collected from patients diagnosed with ameloblastoma through the Oral Pathology 
service at the University of North Carolina from 1998-present. Tumors were obtained 
along with the patients’ clinicopathological and demographic data. Human primary tooth 
germs from 10
th
-19 6/7
th
 week old fetus were obtained from patients undergoing abortion 
through the University of North Carolina Department of Obstetrics & Gynecology. Any 
fetuses with known genetic anomalies or medical conditions were excluded from the 
study. Whole mouse heads were obtained from C57/BL6 at postnatal day 7. All tissue 
samples were fixed in formalin, embedded in paraffin and used for 
immunohistochemistry.  
Immunohistochemistry. Goat anti-mouse WNT5A polyclonal antibody (1:200) 
and recombinant mouse WNT5A were obtained from R&D systems (Minneapolis, MN). 
Specificity and the sensitivity of anti-WNT5A antibody were tested on mouse small 
intestine, hair follicles and liver paraffin embedded sections. Blocking the anti-WNT5A 
antibody with recombinant mouse WNT5A (2 µg/ml) at 4 
o
C overnight was used as a 
negative control. After specificity and sensitivity of the antibody were verified, 
immunohistochemical staining was performed on 4 µm thick, paraffin-embedded sample 
sections using Elite Vectastain kit (Vector Laboratories, Burlingame, CA). 
Deparaffinized sections were preincubated with normal serum to block nonspecific 
binding and then incubated with anti-WNT5A
 
antibody (1:200) at 4 
o
C overnight. A 
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biotinylated rabbit anti-goat antibody
 
was used as the secondary antibody, and 
immunoreaction was visualized
 
using 3, 3'-diaminobenzidine (DAB) substrate kit for 
peroxidase (Vector Laboratories, Burlingame, CA). Sections were counterstained
 
with 
hematoxylin and evaluated for immunoreactivity.
 
 
Statistical analysis. Ameloblastoma samples were categorized into two groups, 
positive and negative, based on expression of WNT5A, and were then compared with 
regard to each clinicopathological variables including age, gender, tumor location and 
histological types. χ 
2 
test was used for statistical analysis and P< 0.05 was considered to 
be statistically significant. 
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RESULTS 
Expression of WNT5A protein in ameloblastoma. First, we validated the 
specificity and sensitivity of anti-WNT5A antibody before using it in further 
experiments. Small intestine and skin from new born mice were used for positive controls 
and adult mouse liver was used as a negative control. Previous studies have shown these 
tissues serve as appropriate positive and negative controls (244-247). Strong WNT5A 
expression was detected in mouse small intestine and hair follicle (Figure 3.1 (a) and (c)) 
since WNT5A is essential for mouse small intestine elongation and hair follicle 
development (244, 246). When recombinant WNT5A (2 µg/ml) was used for antibody 
blocking, the immunoreactivity in both organs was diminished (Figure 3.1 (b) and (d)) 
indicating that anti-WNT5A antibody indeed detected the WNT5A protein. As previously 
reported weak or absent WNT5A expression was observed in adult mouse liver (Figure 
3.1 (e)) (247). 
The results of immunohistochemistry demonstrated the presence of WNT5A 
protein in ameloblastomas (Figure 3.2 (b) and (d)). The epithelial nests and/or strands 
exhibited strong positive staining (Figure 3.2 (e) and (f)). Slight WNT5A expression was 
also detected in the stromal component of ameloblastomas. WNT5A immunoreactivity in 
ameloblastoma was confirmed since the staining in both epithelium and stroma was 
absent when anti-WNT5A antibody was blocked with a recombinant WNT5A protein 
(Figure 3.2 (c)).  
Among our 52 samples of first occurrence, solid/multicystic ameloblastoma, we 
found the major histological tumor subtypes was a mixture of plexiform and follicular 
patterns (44%), followed by follicular (29%) and plexiform (27%) patterns. Expression of 
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WNT5A was observed
 
in 46 ameloblastomas (88%) regardless of the variation in 
histological subtype (Table 3.1). We detected comparable levels of WNT5A expression 
among histologically different ameloblastoma subtypes. Negative WNT5A expression 
was found in 6 cases (12%) and the major subtype of these ameloblastomas was the 
mixed plexiform and follicular pattern (67%). We were able to retrieve the 
clinicopathological features of tumors from 34 cases and the data along with statistical 
analysis are shown in Table 3.1. However, statistical analysis showed no significant 
correlation between WNT5A expression in ameloblastomas and any variables, such as 
age, gender, tumor location, and histological subtypes that we examined. 
Expression of WNT5A protein during mouse and human enamel epithelium 
development. To better understand the possible role of WNT5A in odontogenic tumors, 
we performed immunohistochemical analysis of the WNT5A temporal and spatial 
expression during the development of normal mouse and human teeth. WNT5A 
expression during mouse tooth development demonstrated expression in the dental 
papilla and developing odontoblasts (Figure 3.3 (c) and (d)), but only slight or weak 
expression was present in pre-secretory ameloblasts during the early bell stage (Figure 
3.3 (c) and (d)). Interestingly, during late bell stage, WNT5A expression was also 
detected in mature or secretory ameloblasts (Figure 3.3 (c)) while expression in 
odontoblasts and dental papilla still remained.  
When we performed immunohistochemical analysis using human tooth germs 
(Figure 3.4), the WNT5A expression pattern was remarkably different compared with the 
mouse tooth buds.  Human molars at cap stage (13-16 gestational weeks) showed 
WNT5A localized in both outer and inner enamel epithelium but was weakly detected in 
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dental mesenchyme (Figure 3.4 (a)). During early bell stage (16-18 gestational weeks), 
WNT5A expression was maintained in the inner enamel epithelium, outer enamel 
epithelium and pre-secretory ameloblasts with intense expression around the enamel knot 
and cervical loop areas (Figure 3.4 (c) and (d)). At late bell stage (18-20 gestational 
weeks) when there was some deposition of enamel matrix, WNT5A expression remained 
in the enamel knots and cervical loop areas but was absent from secretory ameloblasts as 
well as dental papilla and developing odontoblasts (Figure 3.4 (e) and (f)). 
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Table 3.1 Clinicopathological features of ameloblastoma in relation to WNT5A     
                expression. 
 
Variable n WNT5A 
positive 
WNT5A 
negative 
χ 
2 
0.05 
 
 
Age 
0-20 
20-40 
>40 
 
Gender 
Male 
Female 
 
34 
9 
13 
12 
 
34 
18 
16 
 
30 
8 
12 
10 
 
30 
16 
14 
 
4 
1 
1 
2 
 
4 
2 
2 
 
 
0.78 
 
 
 
 
0.92 
 
 
 
Tumor location 
Maxilla 
Mandible 
34 
11 
23 
30 
10 
20 
4 
1 
3 
0.73 
Histological types 
Follicular 
Plexiform 
Mixed 
52 
15 
14 
23 
46 
14 
13 
19 
6 
1 
1 
4 
0.53 
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Figure 3.1 Validation of WNT5A antibody specificity.  Strong WNT5A expression 
was detected in mouse small intestine (a) and hair follicles (c) and the immunoreactivity 
was diminished when the antibody was blocked with  recombinant WNT5A (2 µg/ml) 
((b) and (d)). Adult mouse liver was used as a negative control where no expression of 
WNT5A was detected when WNT5A antibody alone (e) and blocked WNT5A antibody 
(f) were used. (Antibody dilution 1:200), (Magnification x100), (Bar, 100 µm) 
 
 
(a) 
(f) (e) 
(c) (d) 
(b) 
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Figure 3.2 Expression of WNT5A in ameloblastoma. Ameloblastomas were 
immunostained with anti-WNT5A antibody (1:200) and images were capture under 100x 
(b and d) and 400x (e and f) magnification. Sections incubated with normal horse serum 
(a) and recombinant WNT5A blocked antibody (c) were used as negative controls. Bar in 
(a)-(d), 100 µm. Bar in (e)-(f), 50 µm. (n=52) 
 
 
 
 
 
 
 
 
 
 
(a) (b) (c) 
(d) (e) (f) 
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Figure 3.3 Expression of WNT5A during mouse tooth development. During the early 
bell stage (EB), intense expression of WNT5A was found in dental papilla (DP in (c) and 
(d)) and developing odontoblasts (OD in (c) and (d)) but slight or weak expression was 
seen in pre-secretory ameloblasts (PAM in (c) and (d)). At the late bell stage (LB), 
WNT5A expression was also detected in mature or secretory ameloblasts (MAM in (c)) 
while expression was sustained in odontoblasts and dental papilla ((LB) in (b)). 
(Antibody dilution 1:200), (Magnification, 40x (a), 100x (b), 400x (c) and (d)), (Bar, 50 
µm), (n=3) 
 
 
 
 
 
 
(a) 
(d) 
(b) 
(c) 
OD 
OD 
DP 
DP 
(c) 
(d) 
EB 
PAM 
EB 
LB 
LB 
PAM 
MAM 
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Figure 3.4 Expression of WNT5A during human tooth development. At the cap stage 
((a) and (b)), WNT5A was localized in both outer (OE) and inner enamel epithelium (IE) 
but weakly detected in dental mesenchyme (DM). During the early bell stage ((c) and 
(d)), WNT5A remained in inner enamel epithelium and pre-secretory ameloblasts (PAM) 
with intense expression around enamel knots (EK) and cervical loops (CL). At the late 
bell stage ((e) and (f)), WNT5A expression remained in enamel knots (EK) and cervical 
loops area (CL) but was absent from mature or secretory ameloblasts (MAM) as well as 
dental papilla (DP) and developing odontoblasts (OD). (Magnification, 40x (c and e), 
100x (a and d), 400x (b and f)), (Bar, 50 µm), (n=3) 
 
 
(b) (a) 
(c) 
(e) 
IE 
OE 
DM (b) 
(d) 
OE PAM EK 
EK 
CL 
DM 
(f) 
EK 
MAM 
CL CL DP 
OD 
DP 
(d) 
(f) 
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DISCUSSION 
Ameloblastomas are the most common epithelial odontogenic tumor and we show 
that they are highly consistent in their expression of WNT5A. While WNT5A expression 
is often associated with malignant tumors, ameloblastomas are benign but locally 
invasive and have a high recurrence rate (32, 40, 41). Detection of WNT5A expression in 
ameloblastoma has been reported by others (81) and our findings in this study also 
suggest the importance of WNT5A during both normal and diseased enamel epithelium 
development.  
In the present study, it is notable that comparable levels of WNT5A expression 
were found in the plexiform, follicular and mixed plexiform/follicular histological 
subtypes, the two most common variants of ameloblastoma. WNT5A expression in 
granular pattern of ameloblastoma was detected in a previous study (81) but the 
expression of WNT5A in other histological subtypes has never been reported. Our study 
found no statistically significant correlation between WNT5A expression and other 
clinicopathological features including patient age, gender, tumor location and histological 
subtypes. A possible reason for this result could be the lack of variety of our samples 
since the recurrence and/or malignant ameloblastomas are excluded. Additionally, only 
partial demographic data were retrievable in our study. Aggressiveness was excluded 
from our variable since all samples are graded as benign tumors. One possible 
explanation could be the locally invasive nature of the tumor, the aggressiveness of 
ameloblastoma is not well characterized or graded and tumors are usually categorized as 
benign (32, 34, 41). Though there is a difference in occurrence rates observed between 
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subtypes, studies report no correlation among each histologically different pattern and 
aggressiveness of ameloblastoma (32, 40, 41).  
The fact that WNT5A is shown to promote cancer aggressiveness and metastasis 
in many types of cancer (168, 188, 229, 231 ) could suggest the possible role of WNT5A 
in ameloblastoma progression. In melanoma, WNT5A was predominantly detected in the 
invading cells at the leading front of cancer invasion while the melanoma cells in other 
areas showed weaker WNT5A expression (168), suggesting the effect of differential 
WNT5A expression on tumor cell behavior. This could be extrapolated to the slow 
growing nature of ameloblastomas that might be regulated by the temporal WNT5A 
expression where tumors actively grow when WNT5A is expressed, and the tumor cells 
are in resting stage when WNT5A expression is downregulated. 
The finding of WNT5A expression during human tooth formation in our study is 
strikingly different from what we and others have observed in mouse. To our knowledge, 
this is the first study of WNT5A expression during human tooth genesis. According to 
previous studies, Wnt5a is strictly expressed in dental mesenchyme but not in enamel 
epithelium during the bud, cap and early bell stages of mouse tooth development (204, 
210). Interestingly, the expression of WNT5A differed between the human and mouse 
teeth and that varied at different developmental stages. Based on previous findings during 
mouse tooth formation, a major role of WNT5A is believed to involve dental 
mesenchyme development (204, 210). Although we cannot detect WNT5A expression in 
dental mesenchyme during human tooth development, the function of WNT5A in dental 
mesenchyme development is still debatable. Since WNT5A is an extracellular protein, a 
gradient of WNT5A expressed from the dental epithelium could influence adjacent 
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mesenchymal induction. In fact, expression of WNT5A in human enamel epithelial cells, 
especially at the enamel knot and cervical loop areas is logical when considering the 
putative roles of WNT5A in promoting cell polarization, tissue patterning and 
gastrulation during embryonic development (230, 248). Directional proliferation of 
enamel epithelium during tooth development is crucial for dental mesenchyme induction, 
tooth cusps patterning and root formation (2, 5). Likewise, cell polarization is an 
important step in ameloblast development (31); hence these processes might be governed 
or modified by WNT5A expression by enamel epithelial cells. 
Enamel epithelial remnants from migrating enamel epithelium in the cervical loop 
areas are believed to give rise to odontogenic tumor (32, 40, 41 ). Interestingly, WNT5A 
expression in ameloblastoma is also intense in the epithelial compartment which is 
similar to WNT5A detection in cervical loop. In the cancer stem cell theory, we know 
that many cancer cells display a stem-cell like phenotype. The potential role of cervical 
loop cells strongly expressing WNT5A is consistent with enamel epithelium remnants 
from cervical loop being the cells giving rise to odontogenic tumors.  
In summary, we demonstrated strong WNT5A expression in the epithelial 
compartment of ameloblastomas. Moreover, we also detected intense WNT5A expression 
in the normal odontogenic epithelial cells that are the origin of cell remnants (epithelial 
rests of Malassez) that gave rise to odontogenic tumorigenesis. These findings led us to 
speculate that WNT5A plays a role in enamel epithelium tumorigenesis. These 
observations led to development of our hypothesis that WNT5A modulates enamel 
epithelium tumorigenicity by promoting aggressive cell behavior which we investigate 
further and present in the Chapter IV and V. 
 CHAPTER IV 
STUDY II 
 
WNT5A modulates tumorigenic behaviors and increases cell migration  
              in enamel epithelium. 
 
Specific aims  
1. To establish and characterize LS-8, enamel epithelium cell, derived stable clones 
expressing higher or lower levels of WNT5A. 
2. To investigate the effect of WNT5A on transforming LS-8 derived stable clones 
behavior by cell transformation 
3. To investigate the effect of WNT5A on LS-8 cell migration 
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INTRODUCTION 
Tumorigenic cells exhibit several characteristics that distinguish them from the 
normal cell counterparts. Most tumor cells share essential changes in cell growth 
properties, including alteration in cell morphology, decreased dependence of growth 
factors, loss of contact inhibition of growth, ability to proliferate in suspension or 
semisolid culture medium, and ability to form tumors when transplanted into an 
immunocompromised host (82, 249). These growth alterations can be evaluated by the in 
vitro and in vivo growth transformation assays that are commonly used to determine the 
tumorigenic growth- regulating properties of oncogenes (249). 
Multitudes of evidence suggest that WNT5A plays essential roles in cancer, 
especially in tumor progression (188). Despite the fact that WNT5A lacks transforming 
activity when introduced to mouse mammary epithelial cells (212, 213), studies show 
WNT5A displays growth promoting activities by increase cell proliferation in both 
progenitors (147, 218, 219) and cancer cells (188, 222), as well as inhibiting apoptosis in 
osteoblast (223) and vascular endothelial cell (221). High levels of WNT5A expression is 
often correlated with a more aggressive phenotype and metastasis of cancers (168, 222, 
236, 237, 250). As previously shown in the chapter III, strong WNT5A expression was 
detected in the epithelial compartment of ameloblastomas leading us to speculate that 
WNT5A might promote aggressive growth behaviors of enamel epithelium. 
In the present study, enamel epithelium cells (LS-8) were used to study the effect 
of WNT5A on enamel epithelium growth behavior. This seemed appropriate since the 
remnants of epithelium from the enamel organ that remains after tooth formation is 
believed to give rise to odontogenic tumors (32, 40, 41). LS-8 cells are derived from 
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enamel organ epithelium extracted form new born mouse first molars that are 
immortalized by simian viral (SV) 40 large T antigen (251). LS-8 cells exhibit 
characteristics of enamel epithelium including the expression and production of enamel 
matrix proteins, such as amelogenin and ameloblastin in a manner similar to primary 
enamel organ epitheliums (251-253).  
In this chapter, effects of WNT5A in modulating tumorigenic growth behaviors of 
enamel epitheliums (LS-8) are demonstrated by in vivo and in vitro cell growth 
transformation assays. Alteration in enamel epithelium cell migration and cytoskeleton 
reorganization by WNT5A overexpression are evaluated by wound healing assay and 
immunofluorescence in the present study. 
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EXPERIMENTAL PROCEDURES 
Cell culture. Mouse enamel epithelium cells established by immortalizing 
primary cultures of new born mouse enamel epithelium with SV40 large T antigen, LS-8 
(generously provided
 
by Dr. Malcolm Snead, University of Southern California), were 
cultured as previously described (251). Briefly, the cells were grown
 
in Dulbecco's 
Modified Eagle's Medium (DMEM) (Sigma-Aldrich, St. Louis, MO) supplemented with 
10% fetal bovine serum (FBS) (Gibco) and 100U/ml penicillin
 
and 100 µg/ml 
streptomycin (Gibco). Cells were maintained in a humidified atmosphere of 95% air and 
5% CO2 at 37
 o
C and culture medium was replaced twice weekly.  
Isolation of Wnt5a cDNA and constructs generation. Total RNA was isolated 
from mouse kidney, which is known to express Wnt5a, using TRIzol reagent (Invitrogen, 
Carlsbad, CA). Two µg of total RNA was used for reverse transcription (RT) and the 
cDNA was synthesized using the Superscript RT kit (Invitrogen) followed by polymerase 
chain reaction (PCR) with primers specific for full length mouse Wnt5a. Primer 
sequences were as follows; 5’-CACCATGAAGAAGCCCATTGG-3’ and 5’-
TTTGCACACGAACTGATCCAC-3’. The PCR products were verified by resolving in 
1% agarose gel with ethidium bromide and photographed under UV light to confirm the 
expected size of the product at 1140 bp. The Wnt5a-PCR products were then ligated into 
pcDNA3.1 V5-His-TOPO mammalian expression vectors (Invitrogen), cloned by using 
TOPO TA cloning kit (Invitrogen). The molecular weight of the ligated insert was 
analyzed by restriction enzymes HindIII and XhoI (New England Biolabs) to demonstrate 
the correct size of full length Wnt5a were inserted in to the vectors. Plasmids were then 
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analyzed by sequencing at the UNC-CH DNA sequencing facility (University of North 
Carolina, Chapel Hill, NC) to determine the correct orientation of the insert.  
Transfection and stable clone establishment. The sense, antisense constructs 
(pcDNA3.1/Wnt5a and pcDNA3.1/ASWnt5a) or pcDNA 3.1/V5-HisA vector (empty 
vector), Invitrogen) were transfected into LS-8 cells using Fugene 6 transfection reagent 
(Roche Applied Science, Indianapolis, IN). After 48 h, cells were trypsinized and plated 
at a low density. Cells were maintained and selected in the presence of G418 (600 µg/ml) 
(Invitrogen) for up to 3-4 weeks to select the stably transfected clones. Single-cell 
derived stable clones were prepared by cloning rings and the expression of WNT5A from 
each clone was analyzed by Western blot.  
Triton X-114 phase separation and Western blot analysis. To ensure the 
WNT5A secretion from stable clones, separation of WNT5A in conditioned medium was 
performed according to the protocol for WNT3 separation with modification (125). In 
brief, conditioned medium collected from stable clones was mixed 1:1 with ice cold 4.5% 
Triton X-114, 150 mM NaCl, 10 mM Tris-HCl, pH 7.5, incubated on ice for 5 min, then 
at 31 °C for 5 min, and centrifuged at 2,000g at 31 °C for 5 min. After two phases of 
Triton X-114 were separated, equal volumes of detergent and aqueous phases were then 
evaluated for the presence of WNT5A using Western blot.  
Since the majority of secreted WNT5A was bound to the proteoglycans 
component of the ECM (200), WNT5A bound to the ECM and cell surface were also 
collected. The WNT5A detected from ECM and cell surface were normalized against β-
actin and were used to compare the level of WNT5A expression.  Cells were washed 
twice with phosphate buffer saline (PBS) and gently lysed in lysis buffer (20mM Tris-
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HCl pH 7.5, 0.5 mM MgCl2, 0.1% TritonX-100) containing the P1860 protease inhibitor 
cocktails (Sigma-Aldrich). The supernatant was collected for analysis.  
Equal volumes of each sample for Western blot analysis were dissolved in sodium 
dodecyl sulfate (SDS) sample buffer (100mM Tris-HCl, pH 8.8, 0.01% bromophenol 
blue, 36% glycerol, and 4% SDS) in the presence of 10mM dithiothreitol (DTT), 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
(Invitrogen) and transferred to nitrocellulose membrane (Biorad). WNT5A protein was 
detected by anti-WNT5A antibody (R&D system) (1µg/ml) and the anti-goat conjugated 
with horse radish peroxidase (HRP) (Santa Cruz) was used as a secondary antibody. β-
actin was detected by anti- β-actin antibody (cell signaling) and the secondary antibody, 
anti-rabbit conjugated with HRP (cell signaling). The immunoreactivity was visualized 
using the ECL Plus kit (GE Healthcare). 
Quantitative real-time PCR. Total RNA was isolated from wildtype LS-8 (WT), 
empty vector clones (EV), LS-8 clones derived overexpressing higher (S) and lower (AS) 
levels of WNT5A using RNeasy kit (Qiagen). Two µg of total RNA was used for RT 
using SuperArray ReactionReady™ First Strand cDNA Synthesis Kit (SA Bioscience) 
containing random primers following the instructions provided in the user's manual. 
Real-time PCR was performed using RT
2 
SYBR Green/ROX qPCR Master Mix (SA 
Bioscience) and sequence specific primers (SA Bioscience). Primers used were as 
follows; Wnt5a (#Mm.287544) and glyceraldehyde-3-phosphate dehydrogenase (Gapdh) 
(#Mm.343110). Real-time PCR was performed on an ABI 7500 Real-Time PCR System 
(Applied Biosystems, Foster City, CA) using the following cycling parameters: 10 min at 
95°C; 40 cycles of 15 sec at 95°C, 1 min at 60°C. Dissociation curve analyses were 
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performed using the instrument's default setting immediately after each PCR run. The 
experiments were done in triplicate. The Wnt5a expression relative to Gapdh was 
determined and the fold changes were calculated by means of 2-∆∆CT method. 
Cell proliferation assay. LS-8 , EV, S and AS clones were seeded in triplicate at 
a density of 1x10
5
 cell/well and maintained in DMEM
 
 containing 10% FBS for 7 days. 
Cells were trypsinized and counted at day 1, 3, 5 and 7. In addition, 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt (MTS) cell proliferation assay (CellTier 96®, Promega) was performed to 
confirm the results. LS-8 , EV, S and AS clones were seeded in triplicate at a density of 
5x10
4
 cell/ml in a 96-well plate and maintained in DMEM
 
 containing 10% FBS for 7 
days. At day 1, 3, 5 and 7 of culture, MTS solution was added into each well followed by 
incubation at 37 °C for 4 h. The amounts of formazan compound, produced by 
metabolically active cells were measured by absorbance at 490 nm. To confirm the 
reproducibility of the results, three independent experiments were performed. 
Growth transformation assays. Serum dependence of cells for growth was 
determined as described previously (249, 254). Briefly, LS-8 , EV, S and AS clones were 
seeded in triplicate at a density of 1x10
5
 cell/well and maintained in DMEM
 
 containing 
10% FBS and allowed to adhere to the culture dish. Then, culture medium was changed 
to DMEM containing 1% FBS and cells were cultured for 7 days. Cells were trypsinized 
and counted at day 1, 3, 5 and 7 to determine cell proliferation and viability. MTS assay 
was also performed as described above in the serum reduced condition to confirm the 
results. 
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To determine the ability of transfected cells to grow as multiple layers and form 
foci, focus formation assay was performed as previously described with modification 
(249, 254). LS-8, EV, S and AS clones were seeded in triplicate of 1x 10
5
 cell/ 60-mm 
cultured dish and maintained in the cultured condition for 3 weeks. After that, cells were 
fixed with 3:1 (v/v) methanol: acetic acid stained with 0.4% crystal violet in 20% ethanol 
and photographed. Stained foci were counted to quantify the transforming activity.
 
 
To determine the anchorage-independent growth, soft agar assay was performed 
as previously described with modification (249, 254). LS-8, EV, S and AS clones were 
cultured as previously described. Monolayer of cells was trypsinized to obtain single-cell 
suspensions. A total of 5 x 10
3
 cells were suspended in DMEM containing 0.3% agar and 
were then seeded onto a 0.5% agar base in six-well plates. DMEM containing 10% FBS 
was added to the top of the agar and was replaced twice weekly. Colony growth was 
assayed at 4 weeks after the initial seed. The number of colonies larger than 50 µm in 
diameter (containing >30 cells per colony) was counted in five random
 
three-dimensional 
fields per well and photographed under 4x objective lens.
  
To confirm the reproducibility 
of the results, three independent experiments for each assay were performed. 
In vivo tumor formation. To evaluate the tumorigenicity of the transfected cells, 
EV cells or cells highly overexpressing WNT5A (SH) were injected subcutaneously into 
the flanks of athymic nude mice (Jackson Labs) at seeding densities of 2×10
6
 cells per 
site. Tumor development was monitored by personnel at animal studies core facility 
(Lineberger comprehensive cancer center, University of North Carolina, Chapel Hill, 
NC). Tumor measurements were taken by calipers three times per week over 12 weeks or 
until the tumor burden reached a volume of 1 cm
3
. At this point, tumors were excised 
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immediately following euthanization, divided in half and fixed in 10% buffered formalin 
for histological analysis or RNAlater solution (Ambion) for RT-PCR. For histological 
analysis, tumors were embedded in paraffin, and sections were cut and stained with 
hematoxylin and eosin. For RT-PCR analysis to confirm the tumor cell origins, total 
RNA was isolated from tumor tissue using TRIzol reagent (Invitrogen). Two µg of total 
RNA was used for reverse transcription and the cDNA was synthesized using the 
Superscript RT kit (Invitrogen) followed by PCR reaction. For WNT5A overexpressing 
tumors, PCR was performed using T7 promoter (5'-TAATACGACTCACTATAGGG-3') 
and Wnt5a (5’-TTTGCACACGAACTGATCCAC-3’) specific primers to generate the 
1150 bp products from pcDNA3.1/Wnt5a plasmid. For tumors formed by the EV group, 
PCR was done using T7 promoter (5'-TAATACGACTCACTATAGGG-3') and BGH (5'-
CTAGAAGGCACAGTCGAGGCT-3') primers to verify the 250 bp products from 
pcDNA3.1 V5-HisA Empty vectors. The PCR products were visualized by resolving in 
1% agarose gel with ethidium bromide and photographed under UV light.  
Wound healing assay. Cells were grown on fibronectin (Sigma-Aldrich) coated 
60-mm dish supplemented with completed medium (10% FBS) to created a monolayer of 
cells. After the cells reached 90% confluence, the medium was switched to 2.5% FBS 
and a wound was created by scratching a line across the monolayer of cells with a pipette 
tip (255). At 17 and 24 h after the scratch, cell migration was monitored. The number of 
cells migrated into the space at 24 h were counted in five random
 
fields per group, 
photographed and fixed with 3:1 (v/v) methanol: acetic acid, and
 
stained with 0.4% 
crystal violet in 20% ethanol. To confirm the reproducibility of the results, five 
independent experiments were performed with two replicates. 
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Actin filament staining. To visualize the change in actin filament organization, 
cells were grown on fibronectin coated glass coverslips, rinsed and fixed with 4% 
paraformaldehyde in PBS for 10 minutes at 4°C. Next, cells were permeabilized in 0.1% 
Triton X-100 in PBS for 10 minutes at 4°C. Actin filaments were stained with a 50 µg/ml 
of fluorescein isothiocyanate (FITC) phalloidin (Sigma-Aldrich) in PBS for 1 h at room 
temperature. The nuclei were counterstained with TOPRO-3 dye (invitrogen) and slides 
were mounted with Vectashield mounting medium (Vector Laboratories). Fluorescent 
images were examined with Olympus FluoView
TM
 FV500 confocal fluorescent 
microscope (Olympus Inc.).  
Statistical analysis. All statistical analyses were performed using Sigma stat 
software. Data were expressed as mean+SD. Statistical differences were determined by 
one-way ANOVA followed by a Tukey-Kramer multiple comparison test at P=0.05. 
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RESULTS 
Establishment and characterization of LS-8 derived stable clones. In order to 
determine the biological consequences of WNT5A expression in enamel epithelium cells, 
we over or underexpressed WNT5A in LS-8 cells. Full length mouse Wnt5a constructs 
were generated using Wnt5a template isolated from mouse kidney by specific PCR 
primers for mouse Wnt5a and were verified as bands at the expected size at 1140 bp 
(Figure 4.1). The Wnt5a-PCR products were then ligated into pcDNA3.1 V5-His-TOPO 
mammalian expression vector and analyzed by sequencing to determine the orientation of 
insert. A search in the database confirmed that the PCR products contained the coding 
region of the mouse Wnt5a cDNA and was 100% identical to the Wnt5a sequence in 
GenBank database. 
We stably transfected LS-8 cell with sense (pcDNA3.1/Wnt5a) or antisense 
(pcDNA3.1/ASWnt5a) constructs and stable clones were selected in the presence of 
G418 (600 µg/ml) in 4-5 weeks after transfection. The EV clones (pcDNA3.1/V5-His B) 
were subjected to the same selection procedure and were used as controls. To ensure the 
secretion of WNT5A protein, expression of WNT5A into the conditioned medium 
generated from each stable clone was verified by Western blot analysis. Due to 
WNT5A’s highly hydrophobic nature, we adopted the Triton X-114 phase separation 
technique to concentrate and maintain solubility of WNT5A in conditioned medium (125, 
200). Results shown in Figure 4.2 (A) illustrate that most secreted WNT5A partitioned to 
the detergent phase (De). Bands at the size of 42 kD (* in Figure 4.2 (A)) represented 
endogenous WNT5A expressed in LS-8 (WT), S and EV clones, while it disappeared 
from AS clone. Bands at approximately 47 kD (arrow in Figure 4.2 (A)) represented 
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WNT5A recombinant proteins which were only expressed in sense transfected clones and 
confirmed the production of WNT5A from transfected constructs. 
When comparing the expression of WNT5A collected from cell surface and cell 
matrices, the level of WNT5A from S clones was classified into 3 groups; high, moderate 
and low overexpression (SH, SM and SL clones) as shown in Figure 4.2 (B). The 
endogenous WNT5A expression in EV clones was comparable to WT, while it was 
suppressed in AS stable clones (Figure 4.3). Expression of Wnt5a in each selected clone 
was then quantified by Real-Time PCR using specific primer with SYBR green detection 
system (Figure 4.4). Average expressions of Wnt5a in SH, SM and SL clones showed 
7.97, 4.5 and 2.3 fold increases respectively when compared to WT and EV clones. 
Wnt5a expression was decreased in selected AS clones by 0.13 fold as confirmed by 
Real-time PCR. Three independent clones from each transfection were selected for the 
subsequent experiments.  
Effects of WNT5A on in vitro cell growth transformation of enamel 
epithelium. We next evaluated the growth properties of selected stable clones by in vitro 
cell growth transformation assay. When seeded on culture dishes, EV, S and AS clones 
showed similar morphology to WT (Figure 4.5). No distinct change in cell morphology 
was observed in any of the groups. Increased expression of WNT5A in enamel 
epithelium did not affect cell proliferation when cells were maintained in medium 
containing 10% FBS (Figure 4.6 (A)). Interestingly, when cultured in serum reduced 
conditions that contained 1% FBS, only the WNT5A overexpressing clones survived in 
the serum starved condition. S clones had dramatically decreased rates of proliferation 
but were still able to survive up to 7 days in culture while WT, EV and AS clones did not 
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survive under reduced serum conditions (Figure 4.6 (B)). This result suggested that 
WNT5A could promote less dependence of growth factor property on enamel epithelium.  
WNT5A overexpressing clones also exhibited loss of contact inhibition of growth 
after confluence when tested with focus formation assay. Allowing growth beyond 
confluence, SH, SM and SL clones continued to divide and form multilayered foci on 
culture dishes for up to 20 days (Figure 4.7 (A)). Few foci were found in WT, EV and AS 
clones where the single layers of cells started to detach from culture dishes after 
confluence (10 days). Interestingly, numbers of foci formed by WNT5A overexpressing 
clones were correlated with the level of WNT5A expression (Figure 4.7 (B)) suggesting 
that WNT5A could promote loss of contact inhibition in enamel epithelium in a dose 
dependent manner.  
Next, we analyzed anchorage-independent growth in these clones by soft agar 
assay. S clones formed visible multiple colonies within 2 weeks after seeding (Figure 4.8 
(A)), whereas WT, EV and AS clones did not form colonies visible by bare eyes even 
after 4 weeks of culture. Similar to what we found in foci formation, the numbers of 
colonies formed in soft agar by WNT5A overexpressing clones corresponded to their 
level of WNT5A expression (Figure 4.8 (B)). 
Finally, we determined if WNT5A overexpression could affect the tumorigenicity 
of LS-8 cells when subcutaneously transplanted into nude mice. SH cells formed palpable 
tumors in the mice within 4 days after injection (Figure 4.9 (A)). Interestingly, EV cells 
also exhibited tumor formation at 18 days after injection. After monitoring for up to 48 
days, all mice in the experiment developed tumors; however SH cells appeared to 
develop tumors earlier than EV control cells. On average, mice injected with SH cells 
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exhibited tumors within 18 days post implantation whereas the EV controls developed 
tumor in 32 days. SH cells also showed a faster tumor growth rate compared to the EV 
group when total tumor volume was calculated (Figure 4.9 (B)). Histology of the tumors 
from both groups appeared to be similar (Figure 4.10 (a) and (c)). They both were 
composed of a mixture of epithelium and mesenchyme. Duct-like or follicular structures 
formed by cuboidal epithelium were found randomly distributed in the tumor with 
mesenchymal cells making up the majority of the tumor. Most of the mesenchymal cells 
were fibroblast-like, poorly differentiate and were in active mitosis as shown by dense 
chromatin condensation. No calcifying areas or tooth forming structures were observed in 
any of the tumors.  
We also performed RT-PCR to confirm the origin of the tumors. For tumors 
formed by SH cells, PCR using T7 forward and Wnt5a reverse primers generated the 
products approximately 1150 bp of the transfected and integrated Wnt5a plasmid (Figure 
4.11 (A)). For tumors formed by EV group, PCR using T7 forward and BGH reverse 
primers yielded the approximately 250 bp bands of integrated pcDNA3.1 V5-HisA 
Empty vectors (Figure 4.11 (B)). The detection of these PCR products indicated that 
tumors formed in nude mice were developed from injected enamel epithelium and not 
from the indigenous mouse cell populations. 
WNT5A increased cell migration and actin polymerization of enamel 
epithelium. Since WNT5A activation has been shown to promote cell migration during 
normal embryonic development as well as tumor metastasis in several types of cancer 
(188), we examined whether or not WNT5A could induce actin filament rearrangement 
to regulate cell migration in enamel epithelium. Scratch wound was created on 90% of 
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confluent monolayer of cell in culture medium containing 2.5% FBS to stimulate cell 
migration. At 17 h after scratching (Figure 4.12, middle row), the highest numbers of 
cells migrating into the created wounds were from S clones, moderate numbers from WT 
and EV and fewest numbers from AS clones. At 24 h (Figure 4.12, lower row), cells from 
S clones were able to close the wound. Although additional cells from WT and EV 
migrated to the space when compared to the results at 17 h, they did not close the wound. 
Interestingly, only small numbers of cell from AS clones migrated into the created wound 
suggesting that WNT5A regulated enamel epithelium cell migration.  
Since the change in stress fiber formation is a necessary process in cell migration 
(109-111), we decided to evaluate the role of WNT5A in this process by actin filament 
staining. Cells were plated on fibronectin coated coverslips. Actin cytoskeleton was 
stained using FITC phalloidin (Figure 4.13). Consistent with the results of our cell 
migration assay, stress fiber formation density was greatly increased in the cells from S 
clones (Figure 4.13, middle row), but largely decreased in the cells from AS clones 
(Figure 4.13, lower row), when they were compared to EV cells (Figure 4.13, upper row). 
Interestingly, filopodia and lamellipodia, structures important for cell migration, were 
generally seen in WNT5A overexpressing cells (Figure 4.13, arrows in middle row), 
while WNT5A underexpressing cells appeared to form clusters with migratory structures 
rarely being seen (Figure 4.13, lower row). These results confirm that WNT5A induces 
enamel epithelium cell migration and this process involves actin cytoskeleton 
reorganization. 
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Figure 4.1 Wnt5a PCR product and restriction enzyme analysis of pcDNA3.1 vectors 
harboring Wnt5a cDNA. The full length-Wnt5a amplicon from mouse kidney is 1140 bp 
(lane 4). pcDNA3.1/Wnt5a digested with HindIII and XhoI demonstrated that the correct 
size of full length-Wnt5a was inserted into the vectors. Uncut pcDNA3.1 vector 
harboring Wnt5a cDNA is seen in lane 1. The sense construct is shown in lane 2 and the 
antisense construct appears in lane 3. Orientation of all inserts was verified by DNA 
sequencing.  
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Figure 4.2 Level of WNT5A protein secretion from different transfection. (A) 
Secreted WNT5A in conditioned medium was partitioned in detergent phase (De) but not 
aqueous phase (Aq) after Triton X-114 phase separation. The 42 kD band of endogenous 
WNT5A (*) was faintly visible in Wild type (WT), overexpressing (S) and empty vector 
(EV) transfections. The 47 kD band of WNT5A fusion protein (arrow) was only detected 
in S transfected clones while WNT5A production was suppressed in AS transfections. 
(B) Stable clones established from S transfection were selected and categorized according 
to level of WNT5A collected from ECM and cell surface into high (SH), moderate (SM) 
and low (SL) overexpressing WNT5A clones.  
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Figure 4.3 Level of WNT5A expression in EV and AS clones. WNT5A bound to ECM 
and cell surface was collected from EV and AS clones. The endogenous WNT5A 
expression (42 kD) in EV clones was comparable to WT, while it was suppressed in AS 
stable clones. Cell lysate from NIH3T3 cells was used as a negative control. Three 
independent clones from each S group, together with EV and AS clones were selected for 
further experiments.  
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Figure 4.4 Quantification of Wnt5a expression in selected stable clones by Real-time 
PCR. Selected stable clones from S transfection showed an increase in Wnt5a expression 
compared with WT and EV clones (2.37, 4.5 and 7.97 fold increase in SL, SM and SH 
respectively). Wnt5a expression in stable clones from AS transfection was decreased by 
0.13 fold. 
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Figure 4.5 Cell morphology of stable clones. No significantly different morphology 
was observed among WT, EV, S and AS clones. When recombinant WNT5A (0.25 
µg/ml) was added to the culture medium, WNT5A treated LS-8 showed similar 
phenotype to WT. (Magnification 200x), (Bar, 100 µm) 
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Figure 4.6 Cell proliferation assays of stable clones. (A), 1 x 10
5
 cells from each clone 
were plated and supplemented with medium containing 10% FBS. Proliferation rates 
were similar among all groups. (B), When the same number of cells were cultured in 1% 
FBS medium, sense clones had a dramatically decreased proliferation rate but still 
survived in serum reduced conditions up to 7 days of culture. WT, EV and AS clones 
could not survive under these conditions. 
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Figure 4.7 WNT5A promoted loss of contact inhibition in enamel epithelium. (A), 
SH, SM and SL formed multilayered foci on culture dishes after being cultured for 3 
weeks while few foci formations were found in WT, EV or AS clones. (B) Numbers of 
foci formation were correlated with the level of WNT5A expression in overexpressing 
clones suggesting a dose dependent effect. 
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Figure 4.8 WNT5A promoted anchorage-independent growth in enamel epithelium. 
(A), S clones formed visible colonies in soft agar within 2 weeks after seeding, whereas 
WT, EV and AS clones failed to form visible colonies by bare eyes. (B), The number of 
colonies formed by S clones corresponded to the level of WNT5A expression. 
(Magnification 40x), (Bar, 200 µm)   
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Figure 4.9 Tumor formation in nude mice. WNT5A overexpressing (SH) or EV-LS-8 
cells (2x10
6
) were subcutaneously transplanted into nude mice (n=8 per group). (A), SH 
cells formed tumors within 4 days after injection. EV groups also exhibited tumor growth 
at 18 days. On average, SH cells exhibited tumors within 18 days post implantation 
compared to 32 days in EV group. (B), SH groups also showed faster tumor growth rates 
when collective total tumor volume was calculated. Tumor formation was monitored for 
up to 83 days. 
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Figure 4.10 H&E staining of tumors formed in nude mice. Tumor histology appeared 
similar in both groups. The majority of the tumor mass was comprised of mesenchyme 
with epithelium that randomly formed duct-like structure. Chromatin condensation was 
found in most of the mesenchymal cells indicating that cells were in active mitosis. 
(Tumor formed by SH cells under 100x (a) and 400x (b). Tumor formed by EV cells 
under 100x (c) and 400x (d) magnification.) (Bar, 50 µm) 
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Figure 4.11 RT-PCR of the tumors formed in nude mice. (A), Bands of integrated 
Wnt5a plasmid approximately 1150 bp were detected in tumors overexpressing WNT5A 
using T7 forward and Wnt5a reverse primers. (B), Tumors formed in the EV group 
yielded the approximately 250 bp band of integrated pcDNA3.1 V5-HisA Empty vectors 
when evaluated using PCR with T7 forward and BGH reverse primers  
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Figure 4.12 WNT5A increased cell migration in enamel epithelium cells. 2x10
6
 of 
cells were seeded onto the fibronectin coated 60-mm dish and supplemented with 2.5% 
FBS in DMEM to create a confluent monolayer. (A), A scratch was made and cell 
migration into the space was monitored at 17 and 24 h. WNT5A overexpressing cells (S) 
showed enhanced migration compared to EV control. In contrast, WNT5A 
underexpressing cells (AS) had greatly decreased cell migration. (B), Number of cells 
migrated into the space were quantified from five random fields. (Magnification 100x), 
(Bar, 100 µm) 
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Figure 4.13 Effect of WNT5A on the morphology and actin cytoskeleton of enamel 
epithelium. (A), Actin cytoskeleton was stained using FITC phalloidin (bright) and 
examined using confocal microscopy. WNT5A overexpressing (S) cells showed a greatly 
increased density of stress fiber formation when compared to EV and AS cells. Filopodia 
and lamellipodia (arrows), were generally seen in WNT5A-S. (B), Number of 
filopodia/lamellipodia were counted and shown as mean+SD value from 20 cells/group.  
(Magnification 600x), (Bar, 20 µm) 
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DISCUSSION 
One major difficulty in studying the molecular pathology of odontogenic tumors 
is the lack of appropriate cell lines and animal models. Attempts by multiple investigators 
show that primary cultured ameloblastoma cells have a very limited life span and 
required immortalizing procedures either by papillomavirus or SV40 large T antigen 
(256, 257). Additionally, relatively normal cell origins are widely used as the models to 
study an early event during tumorigenesis (214, 215). For the cell origin of odontogenic 
tumors, LS-8 cell exhibits several characteristics making it suitable for these studies (251, 
252, 258). LS-8 cells are derived form new born mouse enamel organ (251). The 
remnants of enamel epithelium after completion of tooth formation are believed to give 
rise to odontogenic tumors (32, 40, 41). Until now, LS-8 cells are the most widely use in 
vitro model to study enamel epithelium biology and gene regulation of ameloblast 
development (251-253,258-261).  
Since LS-8 cells are immortalized by SV40 large T antigen, a viral antigen known 
to transform growth of several human cell types (262), the interpretation of our results 
should be done with some caution. It has been reported that ectopic expression of SV40 
small T antigen, but not large T antigen, was required in oncogenic RAS cell growth 
transformation (263, 264) and expression of large T antigen alone was not sufficient for 
cell transformation (262, 265). Interestingly, we observed in in vivo tumor formation 
assays where LS-8 cell populations had already acquired some growth transformation 
properties. This discrepancy might be due to the different transforming susceptibility of 
the SV40 large T antigen in each cell type (262). Though LS-8 and EV cells form few 
colonies in soft agar and tumors in nude mice, statistically significant differences were 
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observed with S cells that showing robust activities in all cell growth transformation 
assays. In the in vivo tumor formation assay, SH cells formed tumors 2 weeks earlier and 
exhibited faster tumor growth rates compared with EV cells. These phenomena could be 
partly explained by the possible function of WNT5A as the oncogenic enhancer.  LS-8 
cells potentially obtained some tumorigenicity from SV40 large T antigen; however, our 
results clearly show that WNT5A enhances tumorigenicity of these cells.  
The role of WNT5A in tumorigenesis, whether it functions as tumor suppressor, 
oncogenic transformer or oncogenic enhancer is still debatable. WNT5A was categorized 
as non-transformed WNT due to the inability to transform mammary epithelial cells (212, 
213), but its transforming property has rarely been tested in other cell models. In fact, 
WNT signaling outcomes are largely dependent on receptor availability (131, 188). 
Given that the expressions of Lrp5/6, Fzd2, -4, -5 and Ror2, the known receptors for 
WNT5A (131, 140, 146), are detected in LS-8 cells by RT-PCR (data not shown), the 
effects of WNT5A on these LS-8 cells are highly anticipated. More recently the line of 
evidence leans towards the fact that the major role of WNT5A in cancer is to promote the 
aggressiveness of cancer cells rather than cancer initiation (188). WNT5A increased cell 
aggressiveness and cell motility when it was expressed in gastric cancer cell and 
melanoma cell (168, 200). Our observations from cell growth transformation assays also 
suggest that WNT5A functions as an enhancer to increase the oncogenic properties in 
LS-8 cells. Whether or not WNT5A can function as an oncogenic transformer is still 
inconclusive. More informative cell and animal models are needed to ultimately answer 
this question. 
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It is notable that histology of the tumors formed in both groups appears to be 
similar with the bulk of the cells being mesenchymal even though the cells being injected 
were epithelial. RT-PCR showed that these tumors developed from the injected enamel 
epithelium cells since the integrated empty vector and Wnt5a plasmids were detected 
from tumor RNA. Although the reasons are not presently known, it is possible that the 
LS-8 cells could have undergone EMT. This change in cell phenotype is found in some 
tumorigenic cells (231, 238). Additionally, WNT5A has been associated with the loss of 
E-cadherin and EMT expression in squamous cell carcinoma (238). Another possible 
explanation is based on the fact that enamel epitheliums are able to induce proliferation 
and differentiation of surrounding mesenchyme (odontoblast during tooth development). 
LS-8 cells might induce improper proliferation and differentiation of surrounding 
mesenchyme and secreted WNT5A from LS-8 cells could function in a paracrine manner 
to help accelerate this process. Although there was no area of tooth forming-like structure 
and no exact match when histology of nude mice tumors was compared to known mouse 
or human odontogenic tumors, these results were not altogether surprising. Since the 
environment at the inoculating sites was considerably different from the jaws, we did not 
expect the similarity of our tumors to any odontogenic tumor. However, since our tumors 
are composed of several duct-like structures, the closest comparison would be 
adenomatoid odontogenic tumor, which is an epithelial tumor that contains duct-like 
structure. Injection of LS-8 cells into the jaw area should be considered in the future 
experiment to create a potentially more appropriate environment for odontogenic tumor 
development. 
  84 
The function of WNT5A in cell migration is another controversial subject 
evaluated by our studies. WNT5A has been shown to suppress migration and invasion of 
breast epithelial cells (232, 241). On the other hand, WNT5A was found to increase cell 
migration and invasion in melanoma cell, fibroblast and breast cancer (168, 227, 228). In 
our study, we found that WNT5A drastically promoted cell migration in LS-8 cells when 
tested by the scratch wound assay. This effect was due to increased cell migration rather 
than cell proliferation since the experiment was done in cultured medium containing 
2.5% FBS and WNT5A had no effect on LS-8 cells when tested with the cell 
proliferation assay. Next, we also investigated if WNT5A increased enamel epithelium 
cell migration via a complex process of actin reorganization. Cells overexpressing 
WNT5A exhibited actin rearrangement and formed protruded membrane structures at the 
edges of the cells when cells were stained with phalloidin. These structures resemble 
lamellipodia and filopodia that produce the force for actively migrating cells. When 
endogenous WNT5A was suppressed in enamel epithelium, AS cells failed to form 
significant actin reorganization and membrane protrusion was rarely seen. Moreover, we 
observed different cell morphology between these cells after the cells were grown on 
fibronectin coated coverslips. S cells were more spread out while AS cells appeared to 
form cell clusters. Therefore, our data indicate a role for WNT5A in regulating enamel 
epithelium cell motility by increasing actin reorganization and extension that generates 
the force for cell movement. 
In summary, our results demonstrate that WNT5A overexpression has multiple 
effects on enamel epithelium cells. WNT5A has the effect of promoting cell survival, 
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instilling a loss of contact inhibition and loss of anchorage dependence, and allowing an 
increase in cell migration, which are all important characteristics of tumorigenic cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER V 
STUDY III 
 
WNT5A promotes tumorigenic behaviors of enamel epithelium via the non-
canonical WNT5A/Rho/JNK pathway 
 
Specific aims  
1. To study the effect of WNT5A on the canonical WNT signaling pathway in 
enamel epithelium by TCF luciferase reporter assay. 
2. To study the effect of WNT5A on the non-canonical WNT signaling pathway in 
enamel epithelium. 
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INTRODUCTION 
 WNT5A is known to initiate multiple downstream signaling pathways, including, 
WNT5A/PCP, WNT5A/calcium and WNT5A antagonized WNT/β-catenin pathways 
(188). These WNT5A pathways are complex and closely cross-talk to others. Studies 
show that WNT5A signals play essential roles, not only during embryogenic 
development but also during tumorigenesis as well as cancer progression (186, 248, 267). 
Our previous data in Chapter IV demonstrated that WNT5A is important for regulating 
enamel epithelium tumorigenicity and motility. In the present study, we attempted to 
identify the downstream signaling mechanisms involved in these processes. The specific 
inhibitors for the known effector proteins in WNT5A signaling pathways were used in in 
vitro cell growth transformation and wound healing assays. The inhibitor approach 
allowed us to evaluate reversed in the tumorigenic phenotype of cells overexpressing 
WNT5A (SH). Finally, the involvement of WNT5A/Rho/JNK pathway in modulating 
tumorigenic behaviors of enamel epithelium was also demonstrated by 
immunohistochemical and Western blot analyses. 
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EXPERIMENTAL PROCEDURES 
Cell culture, transient transfection and luciferase assays. A series of 
experiments were conducted to elucidate whether the canonical or non-canonical WNT 
pathways were involved in WNT5A signaling.  A luciferase assay for the canonical WNT 
signaling pathway was performed as previously described with modification (131, 190). 
LS-8 cells were cultured in DMEM containing 10% FBS at a density of 1x10
5 
cells in a 
6-well plate. Cells were transiently transfected with a TCF reporter plasmid (0.3 µg/well) 
(Topflash), β-galactosidase reporter plasmid (0.2 µg/well) (pCMVβ, Clontech) together 
with pcDNA3.1/Wnt5a (0.75 µg/well) and/or pcDNA3.1/Wnt1 (0.75 µg/well) using 
Fugene 6 transfection reagent (Roche). The total amount of transfected DNA (2 µg/well) 
was kept constant by adding
 
pcDNA3.1/V5 empty vector. In order to determine the dose 
independent effect, luciferase assays were performed in LS-8 cells treated with various 
doses of recombinant WNT5A (0-250 ng/ml) (R&D system). Lef-1 cDNA and Fopflash 
reporter constructs were used as positive and negative controls respectively. At 48 h post-
transfection, luciferase assays were performed using the Luciferase Reporter
 
Assay 
System (Promega). Relative luciferase units were measured and normalized against β-
galactosidase activity. Data were presented as the mean + SD. Each assay was performed 
at least three times. 
Inhibitor treatment and Western blot analysis. LS-8, EV, SH and AS clones 
were cultured in DMEM
 
containing 10% FBS and then treated with inhibitors specific to 
each effector protein known for WNT5A signaling pathways. Inhibitors used were as 
follows; JNK inhibitor (SP600125), RHOA kinase (ROCK) inhibitor (Y27632), CAMKII 
inhibitor (KN93) and PKC isoform inhibitors (Go6983 and GF109203X). All inhibitors 
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were obtained from Sigma-Aldrich. Dimethyl sulfoxide (DMSO) was used as vehicle and 
the final concentration of DMSO was maintained at 20 µl/ml. Inhibitor efficiency was 
verified by Western blot analysis. At 24 h after inhibitor treatment, cells were lysed in 
radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich) containing the P1860 
protease inhibitor cocktail (Sigma-Aldrich) and the P2850 phosphatase inhibitor cocktail 
(Sigma-Aldrich). Supernatant was collected and dissolved in SDS sample buffer (100mM 
Tris-HCl, pH 8.8, 0.01% bromophenol blue, 36% glycerol, and 4% SDS) in the presence 
of 10mM DTT, separated on SDS-PAGE gels (Invitrogen) and transferred to 
nitrocellulose membrane (Biorad). Antibodies used were as follows; anti- phospho-JNK 
(Thr183/Tyr185), anti-total JNK, anti-phospho-PKC (pan), anti-total PKC isoforms, anti- 
total CAMKII (pan), anti- β-actin, and anti-rabbit conjugated with HRP antibodies were 
obtained from cell signaling and were used in 1:1000 dilution. Anti-phospho-CAMKII 
(Thr286) (1:1000) was from Chemicon. The immunoreactivity was visualized using the 
ECL Plus kit (GE Healthcare). The final concentration of inhibitors that inhibited kinase 
activity of targeted proteins, but did not cause cell death was maintained in all further 
experiments in this study. The final concentrations of each inhibitor were as follows; 
SP600125 and Y27632 at 20 µM, KN93 at 25 µM, Go6983 and GF109203X at 1 µM.  
Cell proliferation assay. LS-8 , EV and SH clones were seeded at a density of 
1x10
5
 cell/well and maintained in DMEM
 
containing 10% FBS before adding inhibitors 
for an additional 24 h incubation. Every two days, cells were supplemented with fresh 
medium containing inhibitors. Cells were trypsinized and counted at day 1, 3, 5 and 7. 
Experiments were performed in triplicate. 
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Growth transformation assays. Serum independence of cell growth was 
determined. Briefly, LS-8 , EV and SH clones were seeded in triplicate at a density of 
1x10
5
 cell/well and maintained in DMEM
 
 containing 10% FBS and cells were allowed to 
adhere to the culture dish. Then, the culture medium was changed to 1% FBS containing 
inhibitors followed by 24 h of incubation. Cells were supplemented with fresh medium 
(1% FBS) containing inhibitors every two days. Cells were trypsinized and counted at 
day 1, 3, 5 and 7 to determine cell proliferation and viability.  
Focus formation assay was performed as previously described with modification 
(249, 254). Cells were seeded in triplicate of 1x 10
5
 cell/ 60-mm cultured dish. Culture 
medium containing inhibitors was replaced twice weekly and cells were maintained in 
this cultured condition for 3 weeks. After that, cells were fixed with 3:1 (v/v) methanol: 
acetic acid stained with 0.4% crystal violet in 20% ethanol and photographed. Stained 
foci were counted for quantification of transforming activity.
 
 
To determine the anchorage-independent growth, soft agar assays were performed 
as previously describe with modification (249, 254). Cells were cultured in medium 
containing 10% FBS and the monolayer of cells was trypsinized to obtain single-cell 
suspensions. A total of 5 x 10
3
 cells were suspended in DMEM containing 0.3% agar and 
were then seeded onto a 0.5% agar base in six-well plates. Inhibitors were added to both 
the agar containing the cells and the feeding medium. Completed medium with inhibitors 
was replaced twice weekly. Four weeks after the initial seeding, colony growth was 
assayed by counting the number of colonies (>50 µm in diameter) in five random
 
three-
dimensional fields in each well under 4x objective lens and photographed.
  
To confirm 
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the reproducibility of the results, three independent experiments were performed for each 
assay. 
Wound healing assay. Cells were grown on fibronectin (Sigma-Aldrich) coated 
60-mm dish supplemented with completed medium (10% FBS) to create a monolayer of 
cells. After the cells reached 90% confluence, the medium was switched to 2.5% FBS 
supplemented with inhibitors and a wound was created by scratching a line across the 
monolayer of cells with a pipette tip (255). At 17 and 24 h after the scratch was made, 
cell migration into the created wound was monitored. The number of cells migrated into 
the space were counted in five random fields, photographed and fixed with 3:1 (v/v) 
methanol: acetic acid, and
 
stained with 0.4% crystal violet in 20% ethanol. To confirm 
the reproducibility of the results, five independent experiments were performed in 
duplicate.  
Immunohistochemistry. First occurrence, multicystic/solid ameloblastoma 
tumors were collected from UNC Oral Pathology. Immunohistochemical analysis was 
performed on 4 µm paraffin-embedded sample sections using Elite Vectastain kit (Vector 
Laboratories). Deparaffinized sections were preincubated with normal serum to block 
nonspecific binding and then incubated with an anti-WNT5A
 
antibody (1:200) (R&D 
systems) or anti-phospho-JNK antibody (1:200) (Santa Cruz) at 4 
o
C overnight. A 
biotinylated rabbit anti-goat and goat anti-mouse antibodies
 
were used as the secondary 
antibodies for anti-WNT5A and anti-phospho-JNK antibodies respectively. 
Immunoreaction was visualized
 
by using DAB substrate kit for peroxidase (Vector 
Laboratories, Burlingame, CA). Sections were counterstained
 
with hematoxylin and 
evaluated for immunoreactivity.
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JNK expression and activation assay. EV, S and AS clones were cultured in 
DMEM
 
containing 10% FBS. EV clones were either treated with recombinant WNT5A 
(300ng/ml) (R&D systems) alone for 1 h, pretreated with SP600125 for 1 h followed by 
recombinant WNT5A for additional 1 h of incubation or treated with UV radiation 
(300J/M
2
) for 1 h. Cells were then lysed in RIPA buffer (Sigma-Aldrich) containing the 
P1860 protease inhibitor cocktails (Sigma-Aldrich) and the P2850 phosphatase inhibitor 
cocktail (Sigma-Aldrich). The supernatant was collected and dissolved in SDS sample 
buffer containing 10 mM DTT, separated on SDS-PAGE gels (Invitrogen) and 
transferred to nitrocellulose membrane (Biorad). Western blot analyses were done using 
primary antibody against total JNK, phosphorylated JNK (Thr183/Tyr185) and β-actin. 
Anti-rabbit conjugated with HRP antibody was used as secondary antibody. The 
immunoreactivity was visualized using ECL Plus kit (GE Healthcare). 
Statistical analysis. All statistical analyses were performed using Sigma stat 
software. Data are expressed as mean+SD. Statistical differences were determined by 
one-way ANOVA followed by a Tukey-Kramer multiple comparison test at P=0.05. 
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RESULTS 
WNT5A antagonized WNT canonical pathway in enamel epithelium. It is 
well established that WNT5A can initiate several downstream signaling pathways and the 
effect largely depends on the receptor contexts at the cell surface (131). Studies show that 
WNT5A can antagonize the canonical WNT/β-catenin pathway in several cell types (131, 
139, 189, 190). WNT/β-catenin pathway is known to be critical in regulating normal 
tooth formation; therefore we investigated if WNT5A could inhibit the canonical 
WNT/β-catenin pathway in enamel epithelium by monitoring the activation of Topflash, 
the widely used reporter gene for canonical WNT signaling. 
 When LS-8 cells were transiently cotransfected with the Topflash reporter and 
Wnt1 plasmid, the WNT/β-catenin pathway activator, the luciferase activity of the 
reporter gene was increased by 1.6 fold (Figure 5.1 (A)). When LS-8 cells were 
cotransfected with Wnt5a plasmid (0.75 µg/well) or treated with recombinant WNT5A 
(50 ng/ml), the luciferase activity was decreased by 0.46 and 0.42 fold, respectively. 
Cotransfection of Wnt5a together with Wnt1 in LS-8 cells resulted in greater reduction of 
luciferase activity by 0.24 fold. A similar result was found when Wnt5a plasmid 
transfection was substituted with recombinant WNT5A treatment, the luciferase activity 
was suppressed by 0.32 fold. Moreover, when LS-8 cells were treated with different 
doses of recombinant WNT5A (0-250 ng/ml), the luciferase inductions were inhibited in 
a dose dependent manner (Figure 5.1 (B)). Our results corroborate previous studies in 
other cell types (131, 139, 190), suggesting that WNT5A antagonizes the canonical 
WNT/β-catenin pathway in enamel epithelium. 
  94 
 JNK inhibitor and ROCK inhibitor treatment reversed the tumorigenic 
phenotype of enamel epithelium overexpressing WNT5A. WNT5A is a known ligand 
for different signaling pathways (188). Studies indicate that WNT5A triggers intracellular 
calcium flux leading to the activation of calcium dependent effectors such as CAMKII, 
PKC and NFAT (166, 175, 177).  It is also known that WNT5A/DVL activation can lead 
to increased phosphorylation of JNK (183,184) and involves RHO GTPases and ROCK 
activation (186, 187). In order to identify downstream signals triggered by WNT5A in 
enamel epithelium several inhibitors specific for each effector protein in the pathways 
that are known to be activated by WNT5A were used to treat cells overexpressing 
WNT5A in this study. Dosage use for each inhibitor was determined by Western blot 
analysis (Figure 5.2) and cytotoxicity (data not shown). The working dose was the 
minimum concentration of inhibitors that inhibit kinase activity of targeted proteins, but 
did not cause cell death. Working concentrations of each inhibitor were as follows; 
CAMKII inhibitor (KN93) 25 µM (Figure 5.2 (A)), PKC inhibitors (Go6983 and 
GF109203X) 1 µM each (Figure 5.2 (B)), ROCK inhibitor (Y27632) 20 µM (Figure 5.2 
(C)), and JNK inhibitor (SP600125) 20 µM (Figure 5.2 (D)). DMSO was used as a 
vehicle and the final concentration of DMSO was maintained at 20 µl/ml for each 
inhibitor.  
 In vitro cell growth transformation was performed, together with inhibitor 
treatment, on three independent clones overexpressing WNT5A (SH). First, we evaluated 
the morphology of these cells. When seeded on culture dishes, no change in cell 
morphology was observed at 24 h after inhibitor treatment. All inhibitor treated SH cells 
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showed similar phenotypes to DMSO treatment alone, untreated SH and WT cells 
(Figure 5.3). 
 Inhibitor addition to SH cells did not affect cell proliferation rate when cells were 
maintained in completed medium containing 10% FBS (Figure 5.4). In our previous 
experiment, SH cells survived and proliferated in serum reduced condition that contained 
1% FBS for up to 7 days (Figure 5.5, left upper row). Interestingly, only JNK inhibitor 
(Figure 5.5, right lower row) and ROCK inhibitor (Figure 5.5, left lower row) treatment 
suppressed SH cell survival and proliferation when cells were cultured in the starved 
condition. Other inhibitors had no effect on SH cell survival (Figure 5.5). 
 Additionally, when tested with the focus formation assay, treatment with JNK or 
ROCK inhibitors significantly reduced the numbers of colonies formed by SH cells 
(Figure 5.6). CAMKII inhibitor treated groups also showed lower numbers of colony 
formation but this difference was not statistically significant (P=0.075), whereas PKC 
inhibitor treated cells showed similar numbers of colonies formed when compared to 
DMSO treated group (Figure 5.6). The same results were demonstrated when we 
analyzed anchorage-independent growth in these clones by soft agar assay (Figure 5.7). 
Only treatment with JNK or ROCK inhibitors significantly decreased the numbers of 
colonies formed by SH cells (Figure 5.7) in soft agar when compared to DMSO treated 
and EV controls. Taken together with our in vitro analyses, we concluded that JNK and 
ROCK pathways were associated with the WNT5A induced tumorigenicity of enamel 
epithelium. 
 Previous studies show that activation of JNK and ROCK by WNT5A involves 
regulation of cytoskeleton and subsequent cell migration (186, 187). We therefore 
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investigated the effect of JNK and ROCK inhibitors on SH cell migration. At 24 h after 
the scratch, more SH cells migrated and filled up the created space compared with EV 
control. As we expected, treatment with either JNK or ROCK inhibitors greatly reduced 
the numbers of SH cells that migrated to the created space at 24 h (Figure 5.8, middle and 
right lanes) compared with the vehicle treatment control cells (Figure 5.8, left lane). Our 
results indicated that WNT5A regulated enamel epithelium cell migration via the 
activation of JNK and ROCK pathways. 
 Expression of phospho-JNK in ameloblastoma. Since our inhibitor experiments 
suggested the involvement of the non-canonical WNT5A/JNK pathway in tumorigenicity 
of enamel epithelium, we expected to find the activation of JNK in human ameloblastoma 
samples that were found positive for WNT5A expression from our previous experiment. 
Immunohistochemical analysis was performed on all human ameloblastomas (n=52) to 
detect phosphorylated forms of JNK. When using serial sections, 88.5% (46/52) of 
samples were found positive for both WNT5A and phospho-JNK and 3.8% (2/52) were 
negative for both. However, 7.7% (4/52) were negative for WNT5A but positive for 
phospho-JNK (Table 5.1). Strong phospho-JNK immunoreaction (Figure 5.9, (b), (d) and 
(f)) was detected in the epithelial component of ameloblastomas showing a similar 
expression pattern to WNT5A (Figure 5.9, (a) and (c)). These results provide the first 
connection between WNT5A and activation of JNK in ameloblastoma tumorigenicity and 
suggesting that the WNT5A/JNK pathway could be responsible for certain tumorigenic 
behaviors of enamel epithelium.  
 WNT5A activates JNK phosphorylation in enamel epithelium. It has been 
shown that WNT5A regulates JNK phosphorylation and subsequently changes cell 
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behaviors such as cell migration in several cell types (146, 227, 229, 267). For further 
confirmation, we performed Western blot to check if JNK was activated in our enamel 
epithelium overexpressing WNT5A and that exhibited several tumorigenic properties. 
Treatment of UV radiation (300 J/M
2
) is known to activate JNK in several cell types 
(268, 269) and was used for the positive control in the present study (Figure 5.10, lane 1). 
When using a specific antibody against phosphorylated JNK1 (P-p46) and JNK2 (P-p54) 
at Thr183/Tyr185 (P-Thr183/P-Tyr185), increased phosphorylation of JNK isoforms was 
detected in UV activated- EV, SH and SL cells (Figure 5.10, lane 1, 2 and 3) compared 
with untreated EV control cells (Figure 5.10, lane 7). Moreover, treatment of EV cells 
with recombinant WNT5A (300 ng/ml) for 1 h resulted in activation of JNK (Figure 5.10, 
lane 5) and JNK phosphorylation was inhibited when cells were preincubated with JNK 
inhibitor (20 µM) for 1 h before recombinant WNT5A addition (Figure 5.10 lane 6). 
Interestingly, a similar result was found in AS clones where phosphorylation of JNK1 
and JNK2 was decreased (Figure 5.10, lane 8) compared with EV cells. Taken together, 
our results provide evidence that WNT5A induced tumorigenic behavior of enamel 
epithelium and this process involves activation of the JNK pathway. 
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            Table 5.1 Immunohistochemical analysis of phosphorylated JNK expression in   
                            human ameloblastoma in relation to WNT5A expression. 
 
 
 WNT5A 
positive 
WNT5A 
negative 
Total 
 
P-JNK positive 46 (88.5%) 4 (7.7%) 50 
P-JNK negative 0 (0%) 2 (3.8%) 2 
Total 46 6 52 
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Figure 5.1 WNT5A antagonized Wnt canonical pathway in LS-8 cells. (A) When 
Wnt5a plasmid was cotransfected or recombinant WNT5A (50 ng/ml) was added to LS-8 
cells, the luciferase activity was decreased by 0.46 and 0.42 fold, respectively. 
Cotransfection of Wnt5a plasmid together with Wnt1 resulted in greater reduction of 
luciferase activity to 0.24 fold. (B) When different doses of recombinant WNT5A were 
added (0-250 ng/ml), the luciferase induction was inhibited in a dose dependent manner.  
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Figure 5.2 Working concentration for each inhibitor determined by Western blot. 
(A) CAMKII inhibitor (KN93) 25 µM, (B) PKC inhibitors (Go6983 and GF109203X) 1 
µM each, (C) ROCK inhibitor (Y27632) 20 µM and (D) JNK inhibitor (SP600125) 20 
µM were the minimum concentrations that inhibit kinase activity of the targeted 
proteins, without causing cell death. 
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Figure 5.3 Morphology of enamel epithelium cells overexpressing WNT5A after 24 h 
of inhibitor addition. No cell morphological change was observed after inhibitors were 
added to cells overexpressing WNT5A (SH). All inhibitor treated SH cells showed 
similar phenotypes to DMSO treatment alone, untreated SH and WT cells. 
(Magnification 200x), (Bar, 100 µm) 
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Figure 5.4 Proliferation of cells overexpressing WNT5A in 10% FBS after inhibitor 
addition. Inhibitor addition to SH cells showed no effect on the cell proliferation rate 
when cells were cultured in completed medium containing 10% FBS 
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Figure 5.5 JNK and ROCK inhibitors suppressed survival of cells overexpressing 
WNT5A in 1% FBS. WNT5A-SH cells survived in serum reduced condition for up to 7 
days. When inhibitors were added, only JNK inhibitor (SP600125) and ROCK inhibitor 
(Y27632) suppressed SH cell survival but other inhibitors had no effect on SH cell 
survival.  
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Figure 5.6 JNK and ROCK inhibitors decreased loss of contact inhibition in cells 
overexpressing WNT5A. JNK and ROCK inhibitors significantly reduced the numbers 
of colonies formed by SH cells in the focus formation assay. CAMKII inhibitor (KN93) 
also lowered numbers of formed colonies but the difference was not statistically 
significant (P=0.075), whereas PKC inhibitors (Go6983 and GF109203X) showed similar 
numbers of colonies when compared to DMSO treated group.  
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Figure 5.7 JNK and ROCK inhibitors decreased anchorage-independent growth in 
cells overexpressing WNT5A. JNK and ROCK inhibitors significantly reduced the 
numbers of colonies formed by SH cells in soft agar assay. CAMKII inhibitor (KN93) 
showed lesser colony formation, whereas PKC inhibitors (Go6983 and GF109203X) had 
similar numbers of colonies compared to the DMSO treated group. (Magnification 40x), 
(Bar, 200 µm) 
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Figure 5.8 JNK and ROCK inhibitors suppressed cell migration in cells 
overexpressing WNT5A. (A), 2x10 
6
 of cells were seeded onto the fibronectin coated 
60-mm dish and supplemented with 2.5% FBS. 24 h after the scratch, SH cells migrated 
into most of the space. The addition of JNK or ROCK inhibitors to the SH cells greatly 
impaired SH cell migration compared to DMSO treatment alone. (B), Number of 
migrated cells into the space were counted in five random fields and shown as mean+SD  
(Magnification 100x), (Bar, 100 µm) 
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Figure 5.9 Immunohistochemical analysis of WNT5A and phosphorylated JNK in 
ameloblastomas. 88.5% of ameloblastoma samples were found positive for WNT5A and 
phospho-JNK ((a) and (b)), (c) and (d)), and 3.8% was negative for both ((g) and (h)). 
7.7% was negative for WNT5A but positive for phospho-JNK ((e) and (f)). Both 
WNT5A and phospho-JNK showed similar patterns of immunoreaction with strong 
expression detected in the epithelium component of the ameloblastomas. (Magnification 
100x), (Bar, 100 µm), (n=52) 
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Figure 5.10 WNT5A activates JNK phosphorylation in enamel epithelium cells. 
Phosphorylated JNK1 (P-p46) and JNK2 (P-p54) were increased in UV activated-EV, SH 
and SL (lane 1, 2 and 3) compared to EV alone (lane 7). Treatment of EV cells with 
recombinant WNT5A (300 ng/ml) for 1 h resulted in activation of JNK (lane 5) and JNK 
phosphorylation was diminished when JNK inhibitor (SP600125, 20µM) was added 
before recombinant WNT5A incubation (lane 6). Phosphorylation of JNK1 and JNK2 
was also decreased in AS clones (lane 8) compared with EV cells.  
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DISCUSSION 
 Our previous data indicated that WNT5A is important for mediating enamel 
epithelium tumorigenicity and motility. In these experiments, we investigated the 
signaling mechanisms involved in these processes. Studies show there are multiple ways 
that the non-canonical WNT5A pathway can interact with the canonical WNT/β-catenin 
and the outcomes can be varied depending on cell surface receptors and intracellular 
context (131, 188). Our results indicate that WNT5A antagonizes the WNT/β-catenin 
pathway in enamel epithelium that could have implications during tooth development. 
Studies show that WNT/β-catenin signaling operates at multiple stages of tooth 
morphogenesis and promotes a cascade of several downstream signaling events (202, 
205, 270). Although the canonical WNT signaling pathway is indispensable during 
odontogenesis, WNT/β-catenin signaling must be tightly regulated for establishing 
normal tooth formation. Studies show that gain of function mutation in β-catenin causes 
abnormal dental invaginations and ectopic tooth formation (270). WNT5A might 
function as a regulator or fine tuner of WNT/β-catenin signaling during tooth 
development since its antagonized effect appears to be in a dose dependent manner. This 
hypothesis clearly needs further investigation. 
Our data suggest the involvement of WNT5A/JNK and WNT5A/Rho pathways in 
enamel epithelium tumorigenicity and further indicate that these two pathways are 
closely related. The Rho family of small GTPases are known to activate upstream of JNK 
in variety of cell systems (271-274). However, studies show that activation of RHO 
GTPases is not required for JNK phosphorylation in WNT5A signaling (275). RHO 
GTPases-independent activation of JNK via ROR2 can antagonize WNT/β-catenin 
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signaling (131, 146). Recent studies show that activation of JNK via RHOA results in 
increased cell migration and invasion (267) providing a potential key pathway for 
WNT5A in mediating cancer aggressiveness. Our study supports these previous 
observations. When LS-8 cells overexpressing WNT5A were treated with specific 
inhibitors for each known effector in the WNT5A signaling pathway, similar results were 
observed with JNK and ROCK inhibitors treatment which suppressed cell proliferation in 
reduced serum. Decrease in the loss of contact inhibition and loss of anchorage 
dependence in SH cells were seen when cells were treated with JNK and ROCK 
inhibitors. Our observations also suggest that WNT5A activation through the JNK and 
ROCK pathway is crucial for enamel epithelium cell migration. Reduced expression of 
WNT5A greatly impaired enamel epithelium cell migration and specific JNK or ROCK 
inhibitors were able to diminish the WNT5A-enhancement of cell migration in SH cells. 
Although we have not tested the effect of JNK and ROCK inhibitors on actin 
rearrangement, our results were in line with other studies that shown the increased 
activation of JNK and RHO GTPases coincided with WNT5A increased cell migration 
(222, 227, 229, 267). Interestingly, when we blocked the Rho pathway with a ROCK 
inhibitor the level of JNK phosphorylation was also decreased, suggesting that JNK was 
downstream of RHO and ROCK in enamel epithelium tumorigenesis. Whether there was 
WNT5A/Rho independence JNK activation involved remains unknown. 
Although activation of WNT/calcium pathway is known to play major roles in 
tumor progression and metastasis in many types of cancer (175, 179, 231), our study 
showed different results. We observed no significant change when PKC or CAMKII 
inhibitors were added in the system. However, inhibition of CAMKII seems to partially 
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relieve the effect of WNT5A since we observed a decrease in colony formation in soft 
agar and focus formation assays. In the case of PKC, using either individual or a 
combination (data not shown) of specific PKC isoform inhibitors showed no effect on SH 
cells. Furthermore, the level of phospho-PKC and phospho-CAMKII appeared 
unchanged after WNT5A was over or underexpressed in enamel epithelium cells. These 
data indicate that the WNT5A/calcium pathway is not a major player in WNT5A 
activation in enamel epithelium cells. 
We also demonstrated that the expression of WNT5A coincided with expression 
of phospho-JNK in 92.3% of our samples. This data supports the involvement of 
WNT5A/JNK activation in enamel epithelium tumorigenicity. However, 7.7% of samples 
were found positive for only phospho-JNK but not WNT5A suggesting the existence of 
the non-WNT5A activation of JNK that could play a role in ameloblastoma 
tumorigenicity. 
Finally, we confirmed the activation of JNK by WNT5A in enamel epithelium 
cells. The level of phospho-JNK was dramatically increased when WNT5A was 
overexpressed in enamel epithelium cells and similar results were observed when cells 
were treated with recombinant WNT5A. Taken together, our results provide the first 
demonstration that WNT5A is able to mediate enamel epithelium tumorigenic behaviors 
in multiple ways and WNT5A/RHO/JNK is a key pathway in these processes. 
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CONCLUSIONS 
 
Despite extensive investigations over decades, the molecular determinants 
involved in the initiation, progression and maintenance of odontogenic tumors remains 
poorly understood. It is highly likely that deviance in several critical signaling pathways, 
including the Wnt signals, could play important roles in odontogenic tumorigenesis and 
maintenance. Detection of WNT5A expression in ameloblastomas has been suggested by 
other studies (81), but for the first time our study reports the molecular consequences of 
Wnt5a signaling activation in enamel epithelial cell.  
In this study, we clearly demonstrate that WNT5A expression was intense in both 
the epithelial component of ameloblastoma and in the cervical loops during normal 
human tooth formation. These data suggest the importance of WNT5A during normal and 
diseased enamel epithelium development and provides further support for the assumption 
that enamel epithelium remnants from cervical loop are the cell of origin for odontogenic 
tumors.  
We have also shown that overexpression of WNT5A in enamel epithelium cells 
promoted in vitro tumorigenic characteristics of cell growth, including growth factor 
independence, loss of anchorage dependence, and loss of contact inhibition compared 
with epithelial cells expressing lower levels of WNT5A.  Interestingly, when EV cells 
and cells overexpressing WNT5A were tested for in vivo tumor formation, both of them 
exhibited tumor formation.  However, tumors initiated from cells overexpressing 
WNT5A formed tumors faster than the control cells. Collectively the results of these 
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experiments indicate that WNT5A functions as an oncogenic enhancer in enamel 
epithelium. 
Thirdly, overexpression of WNT5A enhanced cell migration, one of its major 
putative functions, in enamel epithelium compared with LS-8 and EV cells. Increased cell 
motility coincided with increased actin reorganization and filopodia/lamellipodia 
formation, the events important for cell movement. These findings indicate that WNT5A 
can regulate cell migration of enamel epithelium cells. 
Finally, inhibition of JNK and Rho pathways resulted in suppression of 
tumorigenic growth properties of enamel epithelium cells overexpressing WNT5A. In 
addition, JNK and ROCK inhibitors blocked the WNT5A induced increase in cell 
migration observed in enamel epithelium. Increases in the level of phosphorylated JNK 
was observed in enamel epithelium clones overexpressing WNT5A and JNK 
phosphorylation was activated when enamel epithelium cells were treated with 
recombinant WNT5A. These data indicate that WNT5A activates Rho/JNK downstream 
pathway and subsequently modulates enamel epithelium tumorigenicity. 
Based on the results that we observed from this study, it is evident that WNT5A 
potentially modulates aggressive behaviors of enamel epithelial cells via the non 
canonical Wnt5a/Rho/JNK pathway. Furthermore our findings suggest that WNT5A 
could also play an important role during enamel epithelium development since it is 
differentially expressed in enamel knots and cervical loop areas, the signaling centers that 
control adjacent cell development during tooth formation. Aberrance of such signal could 
result in uncontrolled cell growth which we demonstrate in WNT5A induced enamel 
epithelium tumorigenicity.  
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Although our study provides the possible explanation of how WNT5A modulates 
enamel epithelium aggressive behaviors, several aspects still need further investigation. 
For example, it is unclear whether WNT5A has transforming ability in enamel 
epithelium. A more appropriate cell culture and/or animal model is needed to answer this 
question.  
Obviously, the invasive properties of a tumor, such as angiogenesis and ECM 
degradation, are potentially influenced by WNT5A and they have not been addressed in 
the present study. Interestingly we have shown that cells that highly express WNT5A are 
more robust and are able to survive serum deficiency, a feature that could certainly 
enhance continued tumor growth as seen in ameloblastomas.  Development of an 
ameloblastoma cell line will help provide more insight as to the roles of WNT5A in 
odontogenic tumor progression. 
Although the Wnt5a signaling in enamel epithelium can be partly explained by 
our findings, much additional work is clearly needed to elucidate the cascade of WNT5A 
mediating tumorigenic behavior of these cells. Identifying the downstream targets of 
these pathways is of particular interest as they could provide novel therapeutic 
opportunities. Targeted inhibition of WNT5A signaling, especially the Rho/JNK 
pathway, could possibly serve an effective adjunctive therapeutic approach to augment or 
replace radical resection of the jaws that is currently the standard treatment of 
ameloblastomas. These surgeries are frequently associated with marked facial deformity 
making the development of non-surgical approaches highly desirable. The high 
recurrence rate of ameloblastomas, even after radical surgery, also make novel non-
surgical approaches important. 
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Importantly, the putative function of WNT5A during normal tooth development 
needs further investigation. Tooth explant culture using WNT5A bead implantation or 
Wnt5a cre/lox mouse models will provide powerful tools to elucidate the role of WNT5A 
in tooth development and might provide insights for enhancing dental stem cell 
regeneration as occurs in the dental cervical loop.  
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